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A B S T R A C T
Background
Gastro-oesophageal reflux (GOR) is common in infants, and feed thickeners are often used to manage it in infants as they are simple
to use and perceived to be harmless. However, conflicting evidence exists to support the use of feed thickeners.
Objectives
To evaluate the use of feed thickeners in infants up to six months of age with GOR in terms of reduction in a) signs and symptoms of
GOR, b) reflux episodes on pH probe monitoring or intraluminal impedance or a combination of both, or c) histological evidence of
oesophagitis.
Search methods
We used the standard search strategy of the Cochrane Neonatal Review Group to search the Cochrane Central Register of Controlled
Trials (CENTRAL 2016, Issue 2), MEDLINE via PubMed (1966 to 22 November 2016), Embase (1980 to 22 November 2016), and
CINAHL (1982 to 22 November 2016). We also searched clinical trials databases, conference proceedings, and the reference lists of
retrieved articles for randomised controlled trials.
Selection criteria
We included randomised controlled trials if they examined the effects of feed thickeners as compared to unthickened feeds (no treatment
or placebo) in treating GOR in term infants up to six months of age or six months of corrected gestational age for those born preterm.
Data collection and analysis
Two review authors independently identified eligible studies from the literature search. Two review authors independently performed
data extraction and quality assessments of the eligible studies. Differences in opinion were resolved by discussion with a third review
author, and consensus was reached among all three review authors. We used the GRADE approach to assess the quality of the evidence.
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Main results
Eight trials recruiting a total of 637 infants met the inclusion criteria for the systematic review. The infants included in the review
were mainly formula-fed term infants. The trials were of variable methodological quality. Formula-fed term infants with GOR on feed
thickeners had nearly two fewer episodes of regurgitation per day (mean difference -1.97 episodes per day, 95% confidence interval
(CI) -2.32 to -1.61; 6 studies, 442 infants, moderate-certainty evidence) and were 2.5 times more likely to be asymptomatic from
regurgitation at the end of the intervention period (risk ratio 2.50, 95% CI 1.38 to 4.51; number needed to treat for an additional
beneficial outcome 5, 95% CI 4 to 13; 2 studies, 186 infants, low-certainty evidence) when compared to infants with GOR on
unthickened feeds. No studies reported failure to thrive as an outcome. We found low-certainty evidence based on 2 studies recruiting
116 infants that use of feed thickeners improved the oesophageal pH probe parameters of reflux index (i.e. percentage of time pH < 4),
number of reflux episodes lasting longer than 5 minutes, and duration of longest reflux episode. No major side effects were reported
with the use of feed thickeners. Information was insufficient to conclude which type of feed thickener is superior.
Authors’ conclusions
Gastro-oesophageal reflux is a physiological self resolving phenomenon in infants that does not necessarily require any treatment.
However, we found moderate-certainty evidence that feed thickeners should be considered if regurgitation symptoms persist in term
bottle-fed infants. The reduction of two episodes of regurgitation per day is likely to be of clinical significance to caregivers. Due to
the limited information available, we were unable to assess the use of feed thickeners in infants who are breastfeeding or preterm nor
could we conclude which type of feed thickener is superior.
P L A I N L A N G U A G E S U M M A R Y
Feed thickener for infants up to six months of age with gastro-oesophageal reflux
Review question
We reviewed the evidence for the effect of feed thickener on gastro-oesophageal reflux (GOR) in babies up to six months of age.
Background
Gastro-oesophageal reflux is a common condition in babies. It occurs when the stomach contents (milk feeds and acid) come back up
into the gullet or mouth. While this normally improves as babies grow older, it can sometimes become troublesome and treatment may
be needed. Thickening the milk feeds is a simple method that is commonly used to treat GOR. However, it is unclear if using feed
thickeners improves GOR.
Study characteristics
We examined the research published up to 22 November 2016. We found 8 clinical trials recruiting 637 babies up to 6 months of age
who presented with symptoms of GOR. The recruited babies were mainly ’healthy’ term babies (i.e. babies born within three weeks
of the due date) who were bottle feeding. Three of the studies were funded by a pharmaceutical company, hence the quality of the
evidence presented must be interpreted with caution.
Key results
We found that term babies with GOR given feed thickeners had nearly two fewer reflux episodes per day. Babies with GOR were also
2.5 times more likely to have no reflux symptoms if feed thickeners were used. No studies reported information on failure to thrive (i.e.
poor growth). We found that babies with GOR given feed thickeners showed an improvement in an important measure of acid reflux
obtained from pH study. Reflux index (i.e. percentage of time of acidic reflux of pH < 4) was 5% lower in babies given feed thickeners.
No major harms were reported in the eight studies.
Quality of evidence
Due to study design limitations, we are moderately confident in the evidence for the reduction of two reflux episodes per day. Hence,
feed thickeners can be useful in term babies who are bottle feeding and have troublesome GOR.
We rated the quality of the evidence for the other outcomes as low due to the small number of studies with small numbers of babies
recruited. Further research is needed to determine which type of feed thickener is better and whether feed thickeners are useful in babies
with GOR who are breastfeeding or preterm.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Feed thickener compared to control for infants up to 6 months of age with gastro-oesophageal reflux
Patient or population: Formula-fed healthy term infants up to 6 months of age with gastro-oesophageal ref lux
Intervention: Feed thickener
Comparison: Control
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with control Risk with feed thick-
ener
Number of episodes of
regurgitat ion or vomit-
ing per day
assessed with parental
report of symptoms
Follow-up: range 2 to 8
weeks
The mean number of
episodes of regurgita-
t ion or vomit ing per day
was 3 episodes per day
MD 1.97 episodes per
day lower
(2.32 lower to 1.61
lower)
- 442
(6 RCTs)
⊕⊕⊕©
MODERATE 1
Change f rom baseline
value was used for 5
studies. Endpoint value
was used for the re-
maining study due to
insuf f icient data (Chao
2007).
Frequency of regurgi-
tat ion value was used
in preference to f re-
quency of vomit ing in 1
study (Xinias 2005).
Proport ion of infants
without regurgitat ion or
vomit ing at the end
of intervent ion period
(asymptomatic infants)
assessed with parental
report of symptoms
Follow-up: range 1 to 8
weeks
Study populat ion RR 2.50
(1.38 to 4.51)
186
(2 RCTs)
⊕⊕©©
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128 per 1000 319 per 1000
(176 to 576)
Ref lux index (percent-
age of t ime pH <
4) assessed with oe-
sophageal pH probe
study
Follow-up: range 1 to 4
weeks
The mean ref lux index
was 12%.
MD 5.08% lower
(8.89 lower to 1.28
lower)
- 116
(2 RCTs)
⊕⊕©©
LOW 3
Higher ref lux index in-
dicates higher percent-
age of total t ime that
oesophageal pH is less
than 4
Number of ref lux
episodes last ing > 5
minutes assessed with
oesophageal pH probe
study
Follow-up: range 1 to 4
weeks
The mean number of
ref lux episodes last ing
> 5 minutes was 6
episodes
MD 3.4 episodes lower
(5.44 lower to 1.36
lower)
- 116
(2 RCTs)
⊕⊕©©
LOW 3
Durat ion of longest re-
f lux episode
assessed with oe-
sophageal pH probe
study
Follow-up: range 1 to 4
weeks
The mean durat ion of
longest ref lux episode
was 20 minutes.
MD 12.41 minutes
lower
(23.25 lower to 1.58
lower)
- 116
(2 RCTs)
⊕⊕©©
LOW 3
Diarrhoea
assessed with parental
report
Follow-up: range 2 to 8
weeks
- - 511
(6 RCTs)
⊕⊕©©
LOW 4
Insuf f icient data to per-
form analysis. No dif -
ference in diarrhoea in-
cidence or stooling f re-
quency in 4 studies.
17% of infants in the
intervent ion group in
Iacono 2002 and 10%
of total infants in Hegar
2008 withdrew due to
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diarrhoea.
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; MD: mean dif ference; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of the ef fect
1Downgraded one level for serious study lim itat ion. There was unclear risk of bias for allocat ion concealment and high risk
of bias for blinding, as f requency of regurgitat ion was dependent on parental report , who were likely to note the higher
viscosity of the thickened formula.
2Downgraded two levels for: i) serious study lim itat ions (unclear risk of bias for allocat ion concealment and high risk of bias
for blinding, as f requency of regurgitat ion was dependent on parental report , who were likely to note the higher viscosity of
the thickened formula) and ii) serious imprecision (analysis was derived f rom two studies which both contained incomplete
report ing of all measurements but together could be combined).
3Downgraded by two levels for: i) serious study lim itat ion (unclear/ high risk of bias for randomisat ion and allocat ion
concealment) and ii) serious imprecision (lim ited number of studies with small sample size and wide conf idence interval).
4Downgraded by two levels for: i) serious study lim itat ions (unclear risk of bias for allocat ion concealment and high risk of
bias for blinding, as diarrhoea/ side ef fect was dependent on parental report , who were likely to note the higher viscosity of
the thickened formula) and ii) serious publicat ion bias (none of the studies was designed to measure side ef fect/ diarrhoea).
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B A C K G R O U N D
Description of the condition
Gastro-oesophageal reflux (GOR) is an involuntary retrograde
movement of gastric content into the oesophagus with or without
regurgitation (Falconer 2010; Horvath 2008; Vandenplas 2009).
This is a normal physiological, self limiting occurrence in healthy
infants causing little or no symptoms (Czinn 2013; Ferreira 2014;
Vandenplas 2009). Prevalence of regurgitation or GOR in infants
peaks at 4 months of age, with 50% to 85% of infants reported to
have regurgitation at least once a day (Czinn 2013; Nelson 1997;
Neu 2012; Puntis 2015; Sherman 2009).
Transient inappropriate relaxation of the lower oesophageal
sphincter is the main mechanism leading to GOR in most age
groups (Czinn 2013). This was found to occur in preterm infants
as early as 26 weeks’ gestation (Omari 2002). Pharyngeal stimula-
tion, gastric distension, and raised intra-abdominal pressure were
found to trigger the relaxation of the lower oesophageal sphincter.
The role of delayed gastric emptying, another potential mecha-
nism, on the pathophysiology of GOR is unclear (Czinn 2013;
Omari 2002).
With increasing frequency and severity, GOR eventually be-
comes pathological, although this differentiation is difficult to
define. The joint recommendations of the North American So-
ciety for Pediatric Gastroenterology, Hepatology, and Nutrition
(NASPGHAN) and the European Society for PaediatricGastroen-
terology, Hepatology and Nutrition (ESPGHAN) defined gas-
tro-oesophageal reflux disease (GORD) as reflux of gastric con-
tents causing troublesome symptoms or complication, or both
(Vandenplas 2009). The definition of ‘troublesome’ symptoms in
infants is vague due to the non-specific and pervasive nature of
GOR symptoms, reliance on parents or caregiver to report the
symptoms, and the lack of an objective gold standard. Symptoms
such as regurgitation or vomiting and irritable or disordered sleep
can significantly impair quality of life. In an attempt to provide
some objectivity, some authors have suggested that regurgitation
more than four times daily over more than a two-week period in
infants between three weeks and six months old should be desig-
nated as “troublesome” (Vandenplas 2015).
Newborn infants (defined as infants up to 28 days of life) are an in-
teresting group to investigate for GOR, as there are wide variations
in the reported prevalence and clinical course in this age group.
Neonates normally present with GOR at two to three weeks of
age (Meunier 2014), and suffer more frequently probably due to
the liquid diet and supine posture, as compared to older infants
(Ferreira 2014). This is further exaggerated in preterm infants who
also have a shorter and immature oesophagus with non-peristaltic
oesophageal motility (Corvaglia 2013; Neu 2012; Omari 1995),
leading to poor clearance of reflux material from the oesopha-
gus. Other groups of neonates at higher risk of GOR are those
with chronic lung disease, neurological impairment, genetic con-
ditions, or gastrointestinal tract abnormalities such as tracheo-oe-
sophageal fistula (Ferreira 2014). Generally, newborn infants have
a more benign and self limiting clinical course with improvement
in symptoms at 6 months old (Nelson 1997; Puntis 2015), and
spontaneous resolution by 12 to 14 months old as they move to
a more solid diet and acquire neurodevelopmental maturation,
achieving a more upright posture (Ferreira 2014).
However, GOR and GORD are difficult to diagnose in new-
born infants. Unlike with older children and adolescents where
GOR is often diagnosed based on verbally reported symptoms
like heartburn, clinical presentations are more variable in new-
born infants. Regurgitation and irritability are the most com-
mon symptoms described by caregivers (Czinn 2013; Neu 2012).
Other presentations are oesophagitis, haematemesis, apnoea, de-
saturations, bradycardia, and poor growth (Czinn 2013;Orenstein
1993; Puntis 2015; Sherman 2009). A 12-item caregiver-com-
pleted Infant Gastroesophageal Reflux Questionnaire Revised (I-
GERQ-R) is one of the most commonly used questionnaires val-
idated for evaluating treatment response in infants with GOR
(Kleinman 2006; Orenstein 1996). However, studies using the I-
GERQ-R for diagnosing infants with GORD have revealed puz-
zling results (Vandenplas 2009). The questionnaire was found
to lack specificity in differentiating infants with GORD with
symptomatic infants without GORD (Orenstein 2010). Hence,
there is no one symptom or cluster of symptoms that can predict
complications of GOR or treatment response in newborn infants
(Vandenplas 2009). Diagnosis is inferred in an infant when in-
vestigation demonstrates a high frequency or duration of reflux
episodes as well as a clear association between symptoms and milk
reflux without an alternative diagnosis.
Lower oesophageal pH monitoring with or without multiple in-
traluminal impedance (MII) is used to investigate GORD. Poten-
tial of hydrogen monitoring is an objective and sensitive measure
of acidic oesophageal reflux, with established normal ranges based
on pH cut-off value of 4 (Czinn 2013; Vandenplas 2007). The
commonly used measures in pHmonitoring are reflux index (per-
centage of entire record with oesophageal pH < 4), total number
of acidic reflux episodes, number of acid reflux episodes lasting
more than 5 minutes, and the duration of the longest acidic re-
flux episode. However, pH monitoring is insensitive to weak-acid
or non-acid reflux, which may pose an issue in newborn infants,
as their milk diet can buffer the acidic gastric content. Multiple
intraluminal impedance measures changes in electrical impedance
caused by movement of liquid, solid, gas, or mix bolus along the
oesophagus. Hence, the combined MII and pH monitoring of-
fers the ability to measure reflux regardless of pH as well as to
determine the direction, velocity, and height of reflux. However,
normal ranges of MII measures for all age groups are not well es-
tablished and are not consistently reproducible (Corvaglia 2013;
Czinn 2013; Vandenplas 2009). These investigation techniques
may also detect normal variations and are unable to predict sever-
ity of symptoms, prognosis, progression, as well as response to
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treatment (Horvath 2008; Sherman 2009; Vandenplas 2009). Ev-
idence is insufficient for using other investigations like histology,
endoscopy, manometry, barium studies, or nuclear scintigraphy in
diagnosing or excludingGORD(Carroll 2002;Vandenplas 2009).
Description of the intervention
Current guidelines suggest an expectantmanagement strategywith
reassurance and parental education for the management of un-
complicated GOR (Puntis 2015; Vandenplas 2009; Vandenplas
2015). Pharmacological management is usually reserved for in-
fants who fail to respond to conservative management or have
complicated GORD, or both (Corvaglia 2013).
Thickening infant feeds is a simple and commonly used method
in managing regurgitation and GOR in newborn infants (Dhillon
2004; Madhoun 2015). Commonly used feed thickeners include
cereal-based thickenersmade from rice ormaize, gum-based thick-
eners from guar or locust bean, and carboxymethyl cellulose
(Vandenplas 2005; Vandenplas 2015). However, there is variabil-
ity in practices among healthcare professionals in the prescrip-
tion, preparation, and presentation of feed thickening (Madhoun
2015). Apart from the conventional way of thickening the feed by
adding the feed thickeners into the infant’s milk or liquid, there
are now commercially prepared antiregurgitation formulae that
help to reduce variations in preparation. Commercially prepared
antiregurgitation formulae are designed to provide energy density,
osmolality, and nutritional values appropriate to the needs of in-
fants, unlike when thickeners are added to formula feeds (Horvath
2008; Vandenplas 2005; Vandenplas 2015).
The thickening of infant feeds is generally thought to be in-
nocuous. However, there are case series reporting the develop-
ment of necrotising enterocolitis in preterm infants prescribed
xanthan preparations, Beal 2012; Woods 2012, or locust bean
gum thickeners (Clarke 2004). Concerns regarding nutritional
consequences have been raised that include impaired absorption
of nutrients from feeds thickened with indigestible carbohydrate
(Bosscher 2000), and excessive weight gain in infants using rice
cereal as thickener due to higher carbohydrate and lower protein
and fat content in such compositions (Horvath 2008). Gastroin-
testinal symptoms like abdominal pain, diarrhoea, and constipa-
tion are reported in infants using thickened feed (Corvaglia 2013;
Mascarenhas 2005; Vandenplas 2015).
Other conservative management strategies such as small, frequent
feeds may be impractical. This approach may also increase weak-
acid and non-acid GOR episode frequency due to shorter post-
prandial periods (Corvaglia 2013). Positioning the infant on a
head-up slope of up to 45 degrees is commonly used in clinical
practice to manage GOR (Dhillon 2004). However, the evidence
for it reducing acid GOR is lacking (Corvaglia 2013). Positioning
the infant in the prone or left lateral position has been found to
improve GOR but cannot be recommended in infants without
cardiorespiratory monitoring due to the well-established associa-
tion between the risk of sudden infant death syndrome and prone
positioning (Corvaglia 2013).
How the intervention might work
Feed thickener is thought to prevent reflux of gastric content into
the oesophagus by increasing the ‘stickiness’ and weight of the liq-
uid, hence retaining the feed in the stomach (Orenstein 1987). The
maintenance of appropriate viscosity and consistency of thickened
feed is challenging as viscosity varies depending on the type of
liquid into which the feed thickener is added (Almeida 2011), the
dwell time, temperature of liquid, and amount of saliva (Almeida
2011; Hanson 2012).
In contrast, addition of feed thickeners may increase the energy
density and osmolarity of feeds, leading to an increase in the fre-
quency of relaxation of lower oesophageal sphincter and a de-
lay in gastric emptying (Vandenplas 2015), thus worsening GOR
(Minami 1984).
Why it is important to do this review
Gastro-oesophageal reflux is a frequent problem in infants, and
feed thickeners, which are simple to use and perceived to be harm-
less, continue to be prescribed despite the lack of good-quality sci-
entific evidence to support their use. The previous version of this
review, conducted nearly 14 years ago, located no suitable studies
for inclusion. This review was restricted to infants up to 28 days
of age. We have expanded the age of inclusion to six months (or
six months corrected gestational age for those born preterm), as
GOR peaks at four months of age, and GORD continues to be a
problem throughout the first half of infancy.
O B J E C T I V E S
To evaluate the use of feed thickeners in infants up to sixmonths of
age with GOR in terms of reduction in a) signs and symptoms of
GOR, b) reflux episodes on pH probe monitoring or intraluminal
impedance or a combination of both, or c) histological evidence
of oesophagitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We included all randomised controlled trials that examined the
effects of thickening infant formula as compared to unthickened
feeds (no treatment or placebo) on GOR in infants up to six
months of age (six months corrected gestational age for those born
preterm). We included trials reported as abstracts provided we
were able to obtain sufficient information from the abstract or by
contacting the author.
We excluded cross-over studies. Gastro-oesophageal reflux disease
is a condition that spontaneously resolves with age, and therefore
results of cross-over trials are likely to be confounded by the nat-
ural resolution of the condition. Some cross-over studies guarded
against this by using feed thickener and control intervention al-
ternately. However, residual thickened feeds may still be present
in the gastric region due to insufficient washout period.
Types of participants
We included healthy infants with signs or symptoms suggestive
of GOR, or those with a diagnosis of GOR based on 24-hour
ambulatory pH monitoring or oesophagitis on biopsy, or both in
the review.
For this update we included full-term infants less than six months
old or preterm infants up to six months of age corrected for pre-
maturity at the time of inclusion in the trial. We excluded trials
including combined populations of infants within and above this
age criteria if results for infants within this specified age range
were not reported separately from infants above our age criteria.
We attempted to contact the author for this information prior to
exclusion.
Previous versions of this review were restricted to including only
studies in full-term infants up 28 days old and preterm infants
up to 44 weeks corrected gestational age. We have expanded the
age range, as the majority of infants present with GOR after the
first two to three weeks of life (Meunier 2014; Vandenplas 2009;
Vandenplas 2015). Reassurance and parental education are the
usual first-linemanagement for uncomplicated reflux (Vandenplas
2015). Hence, feed thickeners are rarely started by the first 28 days
of life. In addition, the prevalence of GOR peaks at four months
of age, and GORD commonly continues to be a problem until
six months of age, when most infants start having solids in their
diet and acquire the neurological maturity to sit with support in
a more upright posture (Nelson 1997).
We excluded trials whose populations were restricted to infants
with neurological, congenital, or anatomical gastrointestinal tract
abnormalities.
Types of interventions
We included trials reporting the use of thickeners of all types added
to all types of milk, including formula and human milk. This in-
cluded rice-, gum-, or flour-based thickeners, as well as commer-
cially available pre-prepared thickened formulae, which are com-
monly described as antiregurgitation formula. We included trials
reporting the use of Gaviscon Infant (alginate preparation without
antacid). We excluded other preparations of Gaviscon or alginate
with antacid component because theymay have a dual mechanism
of action.
Comparators of interest included no treatment or placebo inter-
ventions that are thought not to affect GOR.
Types of outcome measures
Primary outcomes
1. Symptoms or signs of GOR including:
a) regurgitation, posseting, or vomiting,
b) failure to thrive.
We noted each symptom or sign as a dichotomous and separate
outcome. We note that no sign or symptom is sensitive or specific
to GOR.
We noted number of episodes per day of regurgitation, posseting,
or vomiting separately as continuous outcomes.We used change in
measurement from baseline to the end of the intervention period
in preference to final measurement value. In trials where multiple
measurements were performed, we used only the measurement at
the end of the intervention period.
2. Measures of gastric and oesophageal acidity based on pH mon-
itoring. We included pH probe study parameters of reflux index
(i.e. percentage of time pH < 4) as quantitative discrete variables.
Secondary outcomes
3. Other symptoms or signs of GOR:
a) irritability,
b) disturbed sleep,
c) respiratory symptoms (cough, apnoeas, and recurrent oxygen
desaturation),
d) episodes of bradycardia.
We noted each symptom or sign as a dichotomous and separate
outcome. We noted number of episodes per day of: i) respiratory
symptoms (cough, apnoeas, and recurrent oxygen desaturation)
and ii) bradycardias separately as continuous outcomes. We used
change in measurement from baseline to the end of the inter-
vention period in preference to final measurement value. In trials
where multiple measurements were performed, we used only the
measurement at the end of the intervention period.
4. Other pH probe study parameters included as quantitative dis-
crete variables were:
a) number of reflux episodes per hour,
b) number of reflux episodes lasting > 5 minutes,
c) duration of longest reflux episode.
5. Measure of intraoesophageal intraluminal electrical impedance.
Parameters to be included as discrete quantitative variables were:
a) number of reflux episodes,
b) height of refluxate in the oesophagus,
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c) mean GOR duration of reflux episode.
6. Microscopic evidence of oesophagitis on tissue biopsy. We con-
sidered this as a dichotomous outcome based on the presence or
absence of inflammation.
7. Significant side effects of the therapy, including:
a) bowel obstruction,
b) diarrhoea,
c) aspiration,
d) colic.
Search methods for identification of studies
Electronic searches
For this update we used the criteria and standard methods of
Cochrane and the Cochrane Neonatal Review Group.
We conducted a comprehensive search including: the Cochrane
Central Register of Controlled Trials (CENTRAL 2016, Issue 10)
in the Cochrane Library; MEDLINE via PubMed (1966 to 22
November 2016); Embase (1980 to 22 November 2016); and
CINAHL (Cumulative Index to Nursing and Allied Health Lit-
erature) (1982 to 22 November 2016) using the following search
terms: (“Gastroesophageal Reflux”[Mesh] OR Gastroesophageal
Reflux OR gastro-oesophageal reflux) AND (thick* OR diet
OR antiregurg* OR conserv* OR non-pharmaco* OR nonphar-
maco*), plus database-specific limiters for randomised controlled
trials and neonates (see Appendix 1 for the full search strategies
for each database). We did not apply any language restrictions.
We searched clinical trials registries for ongoing or recently com-
pleted trials (USNational Institutes ofHealthOngoingTrials Reg-
ister ClinicalTrials.gov (clinicaltrials.gov/), the World Health Or-
ganization International Clinical Trials Registry Platform (WHO
ICTRP) (www.who.int/ictrp/search/en/), and the ISRCTN reg-
istry (www.isrctn.com/)). We also searched conference proceed-
ings for the European Society for Paediatric Gastroenterology,
Hepatology and Nutrition (ESPGHAN) and theNorth American
Society for Pediatric Gastroenterology, Hepatology and Nutrition
(NASPGHAN) from 1994 to 2016.
The previous versions of this review used text word terms ’gas-
tro-oesophageal reflux’ or ’gastro-esophageal reflux’, or the MeSH
term ’gastroesophageal reflux’, and the MeSH term ’exp infant,
newborn’. We searched the Cochrane Central Register of Con-
trolled Trials (CENTRAL Issue 2, 2004) in the Cochrane Library,
MEDLINE from 1966 to March 2004, CINAHL from 1982 to
December 2001, and conference and symposia proceedings pub-
lished in Pediatric Research 1990 to 1994. We also searched the
conference proceedings for the European Society for Paediatric
Gastroenterology, Hepatology and Nutrition (ESPGHAN) and
the North American Society for Pediatric Gastroenterology, Hep-
atology and Nutrition (NASPGHAN) from 1994 to December
2001. The searches were not restricted to the English language.
Searching other resources
We searched the reference list of reviews and studies included in
the review.
Data collection and analysis
Selection of studies
Two review authors (TK, SO) independently reviewed all the titles
and abstracts retrieved from the search for eligibility against our
inclusion criteria usingCovidence (Covidence 2015).Weobtained
full-text copies of all potentially eligible studies, which both review
authors independently reviewed.
Differences were resolved by discussion and consensus of the re-
view authors (TK, SO, JD). If necessary, we contacted authors of
the studies for additional data or information.
Data extraction and management
Two review authors (TK, SO) independently extracted data using
a standard data extraction form on Covidence (Covidence 2015).
Differences were resolved by discussion and consensus of the re-
view authors (TK, SO, JD). If necessary, we contacted authors of
the studies for additional data or information.
Assessment of risk of bias in included studies
Two review authors (TK, SO) independently assessed the risk of
bias (low, high, or unclear) of all included trials using theCochrane
‘Risk of bias’ tool for the following domains (Higgins 2011).
• Sequence generation (selection bias)
• Allocation concealment (selection bias)
• Blinding of participants and personnel (performance bias)
• Blinding of outcome assessment (detection bias)
• Incomplete outcome data (attrition bias)
• Selective reporting (reporting bias)
• Any other bias
Any disagreements were resolved by discussion or by a third review
author (JD). See Appendix 2 for a more detailed description of
risk of bias for each domain.
Measures of treatment effect
We reported risk ratios with 95% confidence intervals (CIs) for
dichotomous variables, and mean differences with 95% CIs for
continuous variables. We reported standardised mean differences
with 95% CIs if different measures were used for the continuous
variables. We preferred using change from baseline measurements
to endpoint measurements for continuous variables. We used Re-
view Manager 5 to assess treatment effect of outcome measures
(RevMan 2014).
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Unit of analysis issues
For randomised controlled trials, the infant was designated as the
unit of analysis. For cluster randomised trials, we carried out analy-
ses adjusting for clustering as described in the Cochrane Handbook
for Systematic Reviews of Interventions using the intracluster corre-
lation coefficient derived from the trial or other sources (Higgins
2011).
For multi-arm randomised trials, we pooled together arms report-
ing feed thickeners of different type or different dosage. Arms re-
porting a non-feed thickener intervention were ignored. During
meta-analysis, we would consider an infant only once in the anal-
ysis (i.e. there was no double counting of any groups, including
those infants in the control group) as described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Dealing with missing data
We contacted study authors regarding any missing data or uncer-
tainty about specifics of the study that were vital to the meta-anal-
ysis, and described the contribution of the authors. We derived
missing standard deviations from reported confidence intervals, P
values, or standard errors. If data were still missing, we did not
assume values in order to present the analyses, instead presenting
the information in a descriptive manner.
Assessment of heterogeneity
We assessed heterogeneity between effect size of in the included
studies by visual inspection of the forest plot and Chi2 test for
heterogeneity with a P value of less than 0.1. Inconsistency across
studies and its impact on the meta-analysis were quantified us-
ing I2 statistics and described as percentage of variability in ef-
fect estimates that is due to heterogeneity rather than sampling
error (Higgins 2011).We used Cochrane Neonatal Review Group
guidelines to interpret the I2 statistics as follows.
• less than 25%: no heterogeneity
• 25% to 49%: low heterogeneity
• 50% to 74%: moderate heterogeneity
• greater than 75%: high heterogeneity
If we detected moderate or high heterogeneity (I2 greater than
50%), we explored possible reasons (e.g. differences in study de-
sign, trial participants, interventions, or completeness of outcome
measures) using sensitivity analysis.
Assessment of reporting biases
We assessed potential reporting bias using funnel plots if an indi-
vidual meta-analysis contained more than 10 studies.
Data synthesis
We used a fixed-effect model unless there was substantial hetero-
geneity (I2 greater than 50%) (Higgins 2011). For meta-analyses
with substantial heterogeneity, we explored possible causes of the
heterogeneity using sensitivity analyses.
Quality of evidence
Weused theGRADE approach, as outlined in theGRADEHand-
book (Schünemann 2013), to assess the quality of evidence for the
following (clinically relevant) outcomes:
• number of episodes of regurgitation or vomiting per day,
• proportion of infants without regurgitation or vomiting at
the end of the intervention period,
• reflux index (percentage of time pH < 4),
• number of reflux episodes lasting > 5 minutes,
• duration of longest reflux episodes,
• diarrhoea.
Two review authors independently assessed the quality of the ev-
idence for each of the outcomes above. We considered evidence
from randomised controlled trials as high quality, but downgraded
the evidence one level for serious (or two levels for very serious)
limitations based upon the following: design (risk of bias), consis-
tency across studies, directness of the evidence, precision of esti-
mates, and presence of publication bias. We used the GRADEpro
Guideline Development Tool to create a ‘Summary of findings’
table (Summary of findings for the main comparison) to report
the quality of the evidence (GRADEpro GDT).
The GRADE approach results in an assessment of the quality of
a body of evidence in one of the following four grades.
1. High: We are very confident that the true effect lies close to
that of the estimate of the effect.
2. Moderate: We are moderately confident in the effect
estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
3. Low: Our confidence in the effect estimate is limited: the
true effect may be substantially different from the estimate of the
effect.
4. Very low: We have very little confidence in the effect
estimate: the true effect is likely to be substantially different from
the estimate of the effect.
Subgroup analysis and investigation of heterogeneity
To determine if results differed for term versus preterm infants or
by type of feed thickener, we performed planned a priori subgroup
analyses by inspection of the forest plot for the overlap of confi-
dence intervals and tests for subgroup differences.
Sensitivity analysis
Weperformedmultiple sensitivity analyses to explore the effects of
the methodology of the included trials, excluding trials with high
risk of bias (defined as having more than one domain assessed at
high risk of bias in the ’Risk of bias’ table).
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R E S U L T S
Description of studies
Results of the search
Our initial search yielded 405 reports and conference proceedings.
Based on their abstracts, we examined the full-text reports of 39
promising publications. Of these 39 publications, we excluded
three that were letters or expert opinions on the topic (Craig 2002;
EBP 2004; Savino 2008). There were two publications from the
same study (Gouyon 1988). Hence, we found 35 possibly eligible
studies. Of these, eight matched the inclusion criteria for study
design and types of participants. These are depicted in Figure 1.
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Figure 1. Study flow diagram.
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Included studies
We identified eight suitable studies for inclusion in the updated
review after expanding the age criteria to include infants up
to six months old (see Characteristics of included studies ta-
ble) (Chao 2007; Hegar 2008; Iacono 2002; Miller 1999; Moya
1999; Vandenplas 1994; Vanderhoof 2003; Xinias 2005). Five
of the trials were carried out in North America and Europe in
the 1990s (Iacono 2002; Miller 1999; Moya 1999; Vandenplas
1994; Vanderhoof 2003). These included 3 multicentre trials in-
volving 25 general practices in the UK (Miller 1999), 6 children’s
outpatient centres in Italy (Iacono 2002), and 6 North American
paediatric centres (Vanderhoof 2003). Two trials were carried out
in Taiwan and Indonesia, respectively, in the 2000s (Chao 2007;
Hegar 2008), while Xinias 2005 was a multinational clinical trial
recruiting 96 infants fromGreece, France, Belgium, andMorocco,
also in the 2000s.
Population
A total of 637 infants participated in the included trials (range
20 to 166). The largest of these, Iacono 2002, was published as a
correspondence to the editor only. Most trials included formula-
feeding ’healthy’ term infants presenting with symptoms of GOR
or abnormal oesophageal pH probe parameters, except for Miller
1999, which included formula-feeding and breastfeeding term in-
fants. It was unclear in two studies if preterm infants were in-
cluded as well (Chao 2007; Iacono 2002). Generally, infants with
complicated GORD (e.g. haematemesis, melena), mechanical ob-
struction, atopy, or previous treatment with thickened feeds or
antireflux medication were excluded.
The age criteria specified in the included trials were as follows.
• Up to 3 months: Hegar 2008.
• Up to 4 months: Chao 2007; Iacono 2002; Moya 1999;
Vandenplas 1994; Vanderhoof 2003.
• Up to 12 months: Miller 1999. We decided to include this
study as the spread of infants was likely to be between 3 to 6
months based on the reported mean and standard deviation
value of 4 ± 0.4 months.
• Not stated: Xinias 2005. No age inclusion criteria were
reported. The mean age of recruited infants was 3.1 months (93
days).
The criteria for frequency or symptoms of regurgitation or vom-
iting were as follows.
• ≥ 2 episodes per day or persistent unmanageable
regurgitation/vomiting: Miller 1999.
• ≥ 3 episodes per day: Chao 2007.
• ≥ 4 episodes per day: Hegar 2008.
• > 5 episodes per day: Iacono 2002; Moya 1999; Vandenplas
1994; Vanderhoof 2003.
• Excessive regurgitation or vomiting: Iacono 2002; Xinias
2005.
Two trials specified abnormal oesophageal pH probe parameters
as an inclusion criterion.
• Reflux index > 5%: Xinias 2005.
• Reflux index 10% to 30%: Vandenplas 1994.
Intervention and comparison
Intervention
Four trials used antiregurgitation formula thickened with carob
bean gum (Hegar 2008; Iacono 2002; Moya 1999; Vandenplas
1994). Hegar 2008 had two intervention arms; infants in the
other intervention arm were given standard formula with 5 grams
rice cereal per 100 mL. Vanderhoof 2003 also used pre-prepared
antiregurgitation formula thickened with rice cereal. Three trials
used cornstarch-thickened antiregurgitation formula (Chao 2007;
Moya 1999; Xinias 2005). As noted, Moya 1999 had two inter-
vention arms: one with carob bean gum and the other with corn-
starch-thickened formula.
One trial used alginate without antacid as feed thickener (Miller
1999). Infants weighing more than 4.54 kg were given one sachet
of alginate (0.65 grams alginate). Infants weighing ≥ 4.54 kg
or taking solids were given two sachets of alginate (1.3 grams
alginate).
Control
Standard formula without feed thickeners was used as the control
in trials that used carob bean gum, cornstarch, and rice cereals
as feed thickener. One study used 25% strengthened formula as
their control (Chao 2007), where five measurements of formula
were added to 120 mL of water instead of the recommended four
measurements. Matching placebo was used in the study that used
alginate as feed thickener (Miller 1999).
Co-intervention
Co-interventions were reported in both intervention and control
groups in three studies.
• Parental reassurance: Hegar 2008; Moya 1999; Vandenplas
1994.
• Positional therapy: Vandenplas 1994.
• Adjustment of amount and frequency of feeds: Moya 1999.
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Duration of intervention
• 1 week: Vandenplas 1994.
• 2 weeks: Miller 1999; Moya 1999.
• 4 weeks: Hegar 2008; Xinias 2005.
• 5 weeks: Vanderhoof 2003.
• 8 weeks: Chao 2007; Iacono 2002.
Outcome
Six trials reported number of episodes of regurgitation or vomit-
ing per day (Chao 2007; Hegar 2008; Miller 1999; Moya 1999;
Vanderhoof 2003; Xinias 2005), whereas the remaining two trials
reported the proportion of infants without regurgitation or vomit-
ing at the endof the intervention (Iacono 2002;Vandenplas 1994).
Two trials reported oesophageal pHprobe parameters (Vandenplas
1994; Xinias 2005). The other reported outcomes included non-
regurgitation symptoms and signs (cough, sleep disturbance, and
irritability) and side effects (diarrhoea, constipation, colic, respi-
ratory).
Excluded studies
We excluded 27 studies (see Characteristics of excluded studies
table). We excluded eight studies that recruited infants above six
months old and it was not possible to analyse the group of in-
fants less than six months old separately (Bailey 1987; Borrelli
1997;Chevallier1998; Fabiani 2000;Khoshoo2000; Penna2003;
Tolia 1999; Ummarino 2013). We excluded 14 studies that were
not randomised controlled trials; 10 that were cross-over stud-
ies (Corvaglia 2006; Corvaglia 2011; Corvaglia 2011a; Corvaglia
2012;Gouyon1988;Miyazawa 2006;Miyazawa 2007;Moukarzel
2007; Orenstein 1992; Wenzl 2003); and four that were co-
hort studies (Atasay 2010; Chevallier 2009; Dupont 2016; Xinias
2003). Two trials did not have any suitable controls: Chao 2007a
used infants receiving postural therapy as control, while all three
arms in Georgieva 2016 were formula thickened with carob bean
gum galactomannans in different dosage or temperature. Lasekan
2014 recruited healthy infants without signs or symptoms of
GOR. Ostrom 2006 investigated the effect of soy protein-based
thickened formula versus whey protein-based unthickened for-
mula; the results of this trial are therefore confounded by the effect
of replacement of cow’s milk protein with soy protein. Toporovski
2013 published their study as an abstract without any mention
of the outcome measures specified in this review, and attempts to
contact the authors were unsuccessful.
Of the 27 excluded studies, 8 studies recruited infants that were
exclusively within the neonatal age range defined in the previ-
ous version of the review (Huang 2002), which is full-term in-
fants less than 28 days or preterm infants up to 44 weeks cor-
rected age. However, we excluded these studies as five were cross-
over studies (Corvaglia 2006; Corvaglia 2011; Corvaglia 2011a;
Corvaglia 2012; Gouyon 1988); one was a cohort study (Atasay
2010); one study recruited infants without signs or symptoms of
GOR (Lasekan 2014); and one study investigated the co-interven-
tion of thickened and soy protein-based formula (Ostrom 2006).
Risk of bias in included studies
The trials were of variable methodological quality, as described in
the Characteristics of included studies table and summarised in
Figure 2.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Allocation
We assessed the randomisation method described in two trials to
be at low risk for selection bias (Moya 1999; Vanderhoof 2003).
It was unclear if the randomisation method described adequately
prevented selection bias in five trials (Chao 2007; Hegar 2008;
Iacono 2002; Miller 1999; Xinias 2005). We judged Vandenplas
1994 to be at high risk of selection bias, as infants were randomised
to thickened or unthickened formula in an alternate manner based
on order of presentation to the clinic, which is not true randomi-
sation.
Blinding
We foundblinding of parents andoutcome assessors to be adequate
in the alginate study (Miller 1999), where a matching placebo was
used.
For the remaining studies using rice cereal, cornstarch, and carob
bean gum feed thickeners, the assessment of symptoms or signs
of GOR and side effects depended on parental report. Although
blinding of parents and outcome assessors was attempted, parents
were likely to note the higher viscosity of the thickened formula.
Thismay have affected the parental perceptionof symptoms, signs,
or side effects.
Two studies reported oesophageal pH probe parameters (
Vandenplas 1994; Xinias 2005). The difficulty in blinding parents
to the different viscosity of thickened formula was unlikely to have
affected the objective measure of the pH probe study, hence we
assessed these studies as low risk.
Incomplete outcome data
Five trials achieved complete follow up-assessment. Although 20
infants (22%)withdrew from theMiller 1999 study, their outcome
datawere included in the final analyses, achieving over 90% follow-
up assessment. However, the results excluded two infants from
the control (placebo) group, as they did not receive any study
medication. In two trials (Chao 2007; Vanderhoof 2003), only
81% and 78% of infants completed the eight and five weeks’
follow-up, respectively.However, the outcomemeasures at the end
of study participation in the latter study, Vanderhoof 2003, were
reported in 93% of the infants. This was because the last available
data prior to discontinuation from the study were entered. Chao
2007 excluded 19 infants, including 8 who developed marked
diarrhoea or enteritis, and it was not possible to discern whether
the excluded infants were in the feed thickener or the control
group.
Selective reporting
The largest included study was only published as correspondence
to the editor (Iacono 2002). Hence, not all values for themeasured
outcome and baseline characteristics of the infants were reported.
We assessed reporting bias to be unclear in the remaining trials, as
the study protocol or trial registration number, or both were not
available.
The study protocol or trial registration details were not available
for any of the included studies.
Other potential sources of bias
Three trials declared that they received sponsorship or funding
from pharmaceutical companies (Miller 1999; Vanderhoof 2003;
Xinias 2005). Infants in the intervention group in these three
trials had a higher number of vomiting episodes per day or larger
measure of regurgitation volume than the infants in the control
group. Infants in the intervention group in the Moya 1999 study
were older than in the control group. These differences may have
introduced bias in the final analyses.
Effects of interventions
See: Summary of findings for the main comparison Feed
thickener compared to control for infants up to 6 months of age
with gastro-oesophageal reflux
Primary outcomes
Symptoms or signs or gastro-oesophageal reflux (Outcome
1)
Regurgitation, posseting, or vomiting (Outcome 1a)
Vandenplas 1994 graded the severity of regurgitation using the
Vandenplas scoring system (Vandenplas 1994). Although the im-
provement in the score of severity of regurgitation was found to
be greater with the Saint John’s bread (carob bean gum) thickened
antiregurgitation formula than the control, it did not achieve sta-
tistical significance (mean difference (MD) -1.30 episodes per day,
95% confidence interval (CI) -2.68 to 0.08). Twenty per cent of
infants were found to be asymptomatic in the intervention group
compared to none in the control group at the end of the one-week
intervention (typical risk ratio (RR) 5.00, 95% CI 0.27 to 92.62).
Moya 1999 found that frequency of regurgitation decreased signif-
icantly in the control group as well as in both intervention groups
of cornstarch- and carob flour-thickened formula after two weeks
of intervention. However, the difference in reduction of frequency
was not statistically significant between the control and either in-
tervention groups of cornstarch- (MD-0.60 episodes per day, 95%
CI -5.45 to 4.25) or carob flour-thickened formula (MD -1.20
episodes per day, 95% CI -6.35 to 3.95).
Miller 1999 found a statistically significant greater reduction in
frequency of vomiting or regurgitation in the previous 24 hours in
the alginate group when compared to the control group (median
difference -5.5 versus -2 episodes per day, P = 0.009) after two
weeks of intervention. The alginate group also reported a lower
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severity of vomiting or regurgitation, but this difference did not
achieve statistical significance (P = 0.061). The severity of vomit-
ing or regurgitation was assessed based on the most severe event
recorded in the previous 24 hours on a 4-point Likert scale (none,
mild, moderate, or severe).
Iacono 2002 found that two-thirds of infants were asymptomatic
or improved in both the control and carob flour-thickened an-
tiregurgitation formula groups after eight weeks of intervention.
However, 34% of infants were found to be asymptomatic after
eight weeks of intervention as compared to 14% in the control
group (typical RR 2.39, 95% CI 1.31 to 4.37).
Vanderhoof 2003 found no statistically significant difference in
the reduction of frequency of regurgitation expressed as number
of episodes per day between the control and rice cereal-thickened
formula group (MD-2.00 episodes per day, 95%CI -4.77 to 0.77)
in the five-week intervention period. However, the rice cereal-
thickened group had a borderline statistically significant greater
reduction in frequency of regurgitation expressed as percentage of
feeds with regurgitation (MD -14%, 95% CI -28% to -0.1%).
The study assessed the volume of regurgitation using the total re-
gurgitation volume score, which is a summation of the four largest
regurgitation scores (1 = teaspoon to tablespoon, 2 = tablespoon to
ounce, 3 = ounce to entire feeding, 4 = entire feeding) from each
of the day’s feedings. The rice cereal-thickened group was found to
display a trend towards greater reduction in the total regurgitation
volume score than the control group (MD -1.20, 95% CI -2.59
to 0.19).
Xinias 2005 reported frequency of regurgitation and vomiting sep-
arately based on parental report. Regurgitation was defined as “ef-
fortless passage of refluxed gastric contents into the oral pharynx
and themouth with effortless drooling out of themouth”, whereas
vomiting was defined as “forceful expulsion of the refluxed gas-
tric contents from the mouth”. The cornstarch-thickened formula
group was found to have a greater reduction in the frequency of
regurgitation than the control group that achieved statistical sig-
nificance (MD -2.57 episodes per day, 95% CI -4.28 to -0.86)
at the end of the four-week intervention period. Similiar findings
were reported for the frequency of vomiting (MD -2.54 episodes
per day, 95% CI -4.10 to -0.98).
Chao 2007 found that infants receiving cornstarch-thickened an-
tiregurgitation formula had a statistically significant lower fre-
quency of regurgitation or vomiting at the end of the eight-week
intervention period as compared to the 25% strengthened formula
control group (MD -1.96 episodes per day, 95% CI -2.34 to -
1.58).
Hegar 2008 found a statistically significant decrease in the fre-
quency of regurgitation and vomiting in the control group as well
as in the rice cereal- and bean gum-thickened formula groups after
four weeks of intervention. Although the reduction in frequency
of regurgitation was greater in the intervention groups, the dif-
ference in reduction in frequency when compared to the control
group was not statistically significant in both the rice cereal (MD
-0.90 episodes per day, 95% CI -3.57 to 1.77) and bean gum
groups (MD -1.50 episodes per day, 95% CI -3.25 to 0.25).
Meta-analyses of the regurgitation, posseting, or vomiting
data
Number of episodes of regurgitation, posseting, or vomiting
per day (Outcome 1a)
Sufficient data were reported or obtained from the author to use
change of baseline value in five trials. The Xinias 2005 study
used frequency of regurgitation rather than vomiting. In another
of these five trials, Miller 1999 reported the median number of
episodes of regurgitation rather than the mean. As the sample size
was more than 25, it was assumed that the median and mean were
similar (Hozo 2005), and the standard deviation for the mean dif-
ference was obtained using the reported P value (Higgins 2011).
There was insufficient information in Chao 2007 to report the
change of baseline value, hence the endpoint value was used in-
stead. We felt this would not affect the analysis significantly, as the
baseline values were comparable in the intervention and control
groups (Higgins 2011).
Meta-analysis found that the reduction in frequency of regurgi-
tation or vomiting was significantly greater in infants using feed
thickeners compared to control by nearly 2 episodes per day (MD
-1.97 episodes per day, 95% CI -2.32 to -1.61; 6 studies, 442
infants; I2 = 0%) (Analysis 1.1; Figure 3). This finding remained
the same even after excluding both the Miller 1999 study, which
reported median rather than the mean value, and the Chao 2007
study, which used endpoint value rather than change from base-
line value (MD -1.79 episodes per day, 95% CI -2.78 to -0.80; 4
studies, 273 infants; I2 = 0%).
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Figure 3. Forest plot of comparison: 1 Regurgitation, posseting, or vomiting, outcome: 1.1 Number of
episodes per day.Assumptions1. There was insufficient information in Chao 2007 to report the change of
baseline value, hence we used the endpoint data instead. Change from baseline value was used for the
remaining five studies, where P value was used to determine the standard deviation for the change from
baseline value.2. Frequency of regurgitation rather than vomiting was used for the Xinias 2005 study.3. In
Miller 1999, median number of episodes of regurgitation was reported rather than the mean value. As the
sample size was more than 25, it was assumed that median and mean were similar (Hozo 2005), and the
standard deviation for the mean difference was obtained using the reported P value (Higgins 2011).4. We
halved control groups for Hegar 2008 and Moya 1999, as these were three-arm trials involving one control and
two intervention arms.
Proportions of infants without regurgitation, posseting, or
vomiting at the end of the intervention period (Outcome 1a)
Meta-analysis of data from two trials (186 infants) found that
the infants receiving feed thickeners were 2.5 times more likely
to be asymptomatic from regurgitation or vomiting at the end
of the intervention period when compared to the control. This
finding achieved statistical significance (typical RR 2.50, 95% CI
1.38 to 4.51; typical risk difference (RD) 0.20, 95% CI 0.08 to
0.32; number needed to treat for an additional beneficial outcome
(NNTB) 5, 95% CI 4 to 13) (Analysis 1.2; Figure 4).
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Figure 4. Forest plot of comparison: 1 Regurgitation, posseting, or vomiting, outcome: 1.2 Proportion of
asymptomatic infants.
Failure to thrive (Outcome 1b)
Notrials formally assessed failure to thrive as an outcome, as infants
with failure to thrive due to GOR were usually excluded from the
trials.
Oesophageal pH probe study parameters
Two trials performed oesophageal pH probe study (Vandenplas
1994; Xinias 2005).
Reflux index (Outcome 2)
Meta-analysis of 2 trials (116 infants) detected a statistically sig-
nificant reduction in reflux index in the feed thickener group by
5% when compared to the control group (MD -5.08, 95% CI -
8.89 to -1.28; I2 = 0%) (Analysis 2.1; Figure 5).
Figure 5. Forest plot of comparison: 2 Oesophageal pH probe study parameters, outcome: 2.1 Reflux index
(percentage of time pH < 4).
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Secondary outcomes
Other symptoms or signs of gastro-oesophageal reflux
(Outcome 3)
Irritability (Outcome 3a)
Two studies reported the effect of feed thickeners on irritability.
• Chao 2007: Statistically significant improvement in the
number of infants with irritability in the feed thickener group
(typical RR 0.12, 95% CI 0.02 to 0.93; typical RD -0.18, 95%
CI -0.31 to -0.04; NNTB 6, 95% CI 4 to 25).
• Vanderhoof 2003: No statistically significant improvement
in the percentage of feeds followed by pain in the most
symptomatic quartile of infants at baseline (MD 12%, CI not
given). Percentage of feeds followed by pain was assumed to be a
measure of irritability.
Sleep disturbance (Outcome 3b)
Three studies reported the effect of feed thickeners on sleep dis-
turbance.
• Chao 2007: No statistically significant improvement in the
number of infants with sleep disturbance in the feed thickener
group (typical RR 0.49, 95% CI 0.05 to 5.17; typical RD -0.03,
95% CI -0.11 to 0.06).
• Vanderhoof 2003: Statistically significant improvement in
the percentage of feeds followed by trouble sleeping in the most
symptomatic quartile of infants at baseline (MD 29%, CI not
given; P = 0.03).
• Hegar 2008: No difference in sleep disturbance was
reported between the control and feed thickener groups (no data
reported).
Respiratory symptoms (Outcome 3c)
Two studies reported the effect of feed thickeners on cough.
• Chao 2007: No statistically significant improvement in the
number of infants with cough in the feed thickener group
(typical RR 0.20, 95% CI 0.01 to 3.94; typical RD -0.05, 95%
CI -0.13 to 0.03).
• Vanderhoof 2003: Borderline statistically significant
improvement in the percentage of feeds followed by cough,
choke, or gag at the end of the five-week intervention period
(MD and CI not given; P = 0.049).
Bradycardia (Outcome 3d)
No studies reported this outcome.
Other oesophageal pH probe study parameters (Outcome
4)
Number of reflux episodes per hour (Outcome 4a)
Only one study reported the number of reflux episodes per hour
using the pH probe study. Xinias 2005 found no statistically sig-
nificant reduction in number of reflux episodes per hour (MD -
3.40, 95% CI -7.07 to 0.27).
Number of reflux episodes lasting > 5 minutes (Outcome 4b)
Meta-analysis of 2 trials (116 infants) found a statistically signif-
icant reduction by 3 reflux episodes lasting more than 5 minutes
using the pH probe study in the feed thickener group when com-
pared to the control group (MD -3.40, 95% CI -5.44 to -1.36; I
2 = 0%) (Analysis 2.2; Figure 6).
Figure 6. Forest plot of comparison: 2 Oesophageal pH probe study parameters, outcome: 2.2 Number of
reflux episodes lasting > 5 minutes.
19Feed thickener for infants up to six months of age with gastro-oesophageal reflux (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Duration of longest reflux episode (Outcome 4c)
Meta-analysis of 2 trials (116 infants) found that infants in the feed
thickener group had statistically significant shorter reflux episodes
detected by the pH probe study by 12.4 minutes when compared
to the control group (MD -12.41 minutes, 95% CI -23.25 to -
1.58; I2 = 7%) (Analysis 2.3; Figure 7).
Figure 7. Forest plot of comparison: 2 Oesophageal pH probe study parameters, outcome: 2.3 Duration of
longest reflux episode (minutes).
Intraoesophageal intraluminal electrical impedance
(Outcome 5)
No studies used intraoesophageal intraluminal electrical impe-
dence.
Microscopic evidence of oesophagitis on tissue biopsy
(Outcome 6)
No studies performed endoscopy to obtain tissue biopsy of the
oesophagus. Vandenplas 1994 performed upper gastrointestinal
endoscopy with biopsies for histology at baseline in 11 infants for
whom there was suspicion of peptic oesophagitis. No postinter-
vention endoscopies were performed.
Side effects (Outcome 7)
Two trials reported that there was no recorded side effects in any of
the infants participating in the study (Moya 1999; Xinias 2005).
Bowel obstruction (Outcome 7a)
There were no reported incidences of bowel obstruction in any of
the eight included studies. Miller 1999 found no difference in the
incidence of constipation between the alginate and control groups
(typical RR 4.38, 95% CI 0.51 to 37.65; typical RD 0.07, 95%
CI -0.02 to 0.17).
Diarrhoea (Outcome 7b)
Six trials reported on the effect of intervention on bowel move-
ments.
• Miller 1999: No statistically significant difference in the
incidence of diarrhoea between the alginate and control groups
(typical RR 0.85, 95% CI 0.35 to 2.08; typical RD -0.03, 95%
CI -0.19 to 0.13).
• Moya 1999: No statistically significant difference in the
reduction in number of stools per day was noted between the
control and cornstarch-thickened group (MD -0.22 episodes per
day, 95% CI -1.33 to 0.89). We could not determine standard
deviation for the reduction in frequency of stooling in the carob
flour-thickened group from the information available. However,
there were no reported differences in the frequency of stooling
before and after starting carob flour-thickened formula.
• Iacono 2002: Intervention was suspended in 14 infants in
the carob flour-thickened group due to diarrhoea. The number
of infants in the control group with diarrhoea was not reported.
• Xinias 2005: There was no significant difference in the
reduction of number of stools per day in the cornstarch-
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thickened formula group versus the control group (MD 0.24,
95% CI -1.58 to 2.06).
• Chao 2007: Eight infants did not complete the eight-week
study due to diarrhoea. The proportion of these infants in the
feed thickener or control group was not reported.
• Hegar 2008: Consistency and frequency of stools were
reported not to differ between the feed thickener and control
groups. A majority of infants were reported to have normal soft
stools.
Aspiration (Outcome 7c)
No trials reported cases of aspiration during the study period.
Colic (Outcome 7d)
Only one trial reported the effect of feed thickeners on the inci-
dence of colic (Miller 1999), finding no difference in the incidence
of colic between the alginate and control groups (typical RR 0.73,
95% CI 0.13 to 4.16; typical RD -0.02, 95% CI -0.11 to 0.08).
Subgroup analyses
We carried out the following a priori subgroup analyses.
Term or preterm infants
No trials were performed on preterm infants.
Type of feed thickener
• Number of episodes of regurgitation, posseting, or
vomiting per day (Outcome 1a): No significant interaction
existed between the subtotal estimates for the type of feed
thickener (Chi2 = 2.02, df = 3, P = 0.57) (Analysis 1.1; Figure 3).
◦ Rice cereal: MD -1.43 episodes per day, 95% CI -3.36
to 0.49; 2 studies, 127 infants; I2 = 0%.
◦ Carob bean gum: MD -1.47 episodes per day, 95% CI
-3.13 to 0.19; 2 studies, 39 infants; I2 = 0%.
◦ Cornstarch: MD -1.98 episodes per day, 95% CI -
2.35 to -1.61; 3 studies, 188 infants; I2 = 0%.
◦ Alginate: MD -3.50 episodes per day, 95% CI -6.07 to
-0.93; 1 study, 88 infants.
• Proprotions of infants with regurgitation, posseting, or
vomiting at the end of the intervention period (Outcome 1a):
Both studies used carob bean gum feed thickener.
• Reflux index (Outcome 2): No significant interaction
existed between the subtotal estimates for the type of feed
thickener subgroups (Chi2 = 0.35, df = 1, P = 0.55) (Analysis
2.1; Figure 5).
◦ Carob bean gum: MD -3.90%, 95% CI -9.36 to 1.56;
1 study, 20 infants.
◦ Cornstarch: MD -6.20%, 95% CI -11.50 to -0.90; 1
study, 96 infants.
• Number of reflux episodes lasting > 5 minutes (Outcome
4b): No significant interaction existed between the subtotal
estimates for the type of feed thickener (Chi2 = 0.35, df = 1, P =
0.55) (Analysis 2.2; Figure 6).
◦ Carob bean gum: MD -3.40, 95% CI -7.06 to 0.26; 1
study, 20 infants.
◦ Cornstarch: MD -3.40, 95% CI -5.85 to -0.95; 1
study, 96 infants.
• Duration of longest reflux episode (Outcome 4c): No
significant interaction existed between the subtotal estimates for
the type of feed thickener (Chi2 = 1.07, df = 1, P = 0.30)
(Analysis 2.3; Figure 7).
◦ Carob bean gum: MD -1.80 minutes, 95% CI -24.63
to 21.03; 1 study, 20 infants.
◦ Cornstarch: MD -15.50 minutes, 95% CI -27.81 to -
3.19; 1 study, 96 infants.
Sensitivity analyses
We carried out the following sensitivity analyses. The first analysis
was a predetermined a priori analysis, while the second analysis
was performed to explore the effect of using endpoint value rather
than change from baseline value in the analysis.
Effect of methodology of trials
As the included trials relied upon parental report for symptoms
or signs and side effects, we combined the blinding of participant
and personnel with blinding of outcome assessors as one risk of
bias. We assessed six trials as having more than one rating of high
risk of bias in our analysis.
• We re-performed meta-analysis of the number of episodes
of regurgitation or vomiting per day (Outcome 1a) using data
from the remaining two studies (Hegar 2008; Miller 1999),
which showed similar results (MD -1.86, 95% CI -3.13 to -0.58;
2 studies, 148 infants; I2 = 10%).
Trials reporting the remaining outcome measures had more than
one rating of high risk of bias.
Endpoint value effects
We re-performed the following five outcome measures using end-
point value. The results we obtained were similar to those previ-
ously stated.
• Number of episodes of regurgitation, posseting, or
vomiting per day (Outcome 1a): MD -1.91 episodes per day,
95% CI -2.24 to -1.58; 5 studies, 345 infants; I2 = 0% (Analysis
3.1; Figure 8).
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Figure 8. Forest plot of comparison: 3 Sensitivity analysis, outcome: 3.1 Endpoint value - number of
episodes of regurgitation, posseting, or vomiting per day.
• Reflux index (Outcome 2): MD -4.01%, 95% CI -6.33 to
-1.68; 2 studies, 116 infants; I2 = 0% (Analysis 3.2).
• Number of reflux episodes lasting > 5 minutes (Outcome
4b): MD -2.24, 95% CI -3.62 to -0.85; 2 studies, 116 infants; I2
= 0 (Analysis 3.3).
• Duration of longest reflux episode (Outcome 4c): MD -
8.09 minutes, 95% CI -11.93 to -4.25; 2 studies, 116 infants; I2
= 0% (Analysis 3.4).
D I S C U S S I O N
Summary of main results
Meta-analysis of the included studies found that usage of feed
thickeners reduced the frequency of regurgitation or vomiting by
two episodes per day when compared to control. The evidence was
of moderate quality due to serious study limitations (Summary of
findings for the main comparison). There was unclear risk of bias
in allocation concealment and high risk of bias for blinding, as
frequency of regurgitation was dependent on parental report who
were likely to note the higher viscosity of the thickened formula.
These limitations lowered our confidence in the effect estimate.
The 95% confidence interval for the estimate of effect was nar-
row, consistent with a reduction of between 1.6 to 2.3 episodes
per day. Chao 2007 had the highest weight in the meta-analysis,
of 85%, due to its smaller standard deviation and larger sample
size compared to the other five studies included in the analysis.
However, the smaller standard deviation could be a result of using
the endpoint score rather than the change from baseline due to
insufficient information in the report. This finding remained after
removing two studies (Chao 2007 for the usage of endpoint scores
rather than change from baseline score, and Miller 1999 due to
the reporting of median rather thanmean values), withmore equal
distribution of weight across the remaining four studies, ranging
from 4% to 34%. The repeat meta-analysis of the remaining four
studies found that feed thickeners reduced frequency of regurgita-
tion or vomiting by 1.8 episodes per day with 95% confidence in-
terval of reduction between 0.8 and 2.8 episodes per day. Although
only the cornstarch- and alginate-thickened groups showed sig-
nificant reduction in the frequency of regurgitation or vomiting
(Figure 3; Figure 4), we found no significant interaction between
the subtotal estimates for the type of feed thickener subgroups.
This may because there are very few studies in each feed thickener
subgroup.
We also found infants given feed thickeners to be 2.5 times more
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likely to be asymptomatic from regurgitation or vomiting at the
end of the intervention period compared to control infants. How-
ever, this evidence was of low quality (Summary of findings for the
main comparison). Besides the serious study limitationmentioned
above, there was serious imprecision. This analysis was derived
from just two studies, including the largest study in the review
recruiting 166 infants (Iacono 2002), which was reported as an
abstract only. Results for whether feed thickeners improved non-
regurgitation signs or symptoms were conflicting.
We also found usage of feed thickeners to improve the oesophageal
pH probe parameters of reflux index by 5%, the number of re-
flux episodes lasting more than 5 minutes by 3.4 episodes per
day, and the duration of longest reflux episodes by 12.4 minutes
when compared to control. However, the evidence for these find-
ings was of low quality due to serious study limitation (unclear/
high randomisation and allocation concealment bias) as well as
imprecision (Summary of findings for the main comparison). The
analyses were based on two trials with a total of 116 infants. Only
one trial in 96 infants reported the number of reflux episodes per
hour detected by oesophageal pH probe, and did not show any
difference.
There was no significant difference in the incidence of side effects
reported between the control and feed-thickened groups in the
majority of the included studies except for Iacono 2002, where
the intervention was suspended in 14 infants (17%) in the carob
flour-thickened group due to diarrhoea. The number of infants in
the control group with diarrhoea was not reported in this study.
Similarly, the evidence for these findings was of low quality due
to serious imprecision and publication bias. None of the studies
was designed to measure side effects (Summary of findings for the
main comparison).
Overall completeness and applicability of
evidence
Firstly, these findings are broadly applicable only to formula-feed-
ing term infants up to six months of age presenting with uncom-
plicated GOR diagnosed by clinical symptoms, including the fre-
quency of regurgitation. These findings may not be applicable to
preterm infants despite reflux being a common problem in this
group (Drug and Therapeutics Bulletin 2010). The lack of stud-
ies in preterm infants may be due to the difficulty in diagnos-
ing or measuring GOR in preterm infants as well as the lack of
feed thickeners that meet the nutritional demands of preterm in-
fants (Corvaglia 2013). The use of alginate in preterm infants was
found to reduce the acid oesophageal exposure detected by com-
bined pH and impedence monitoring (pH-MII) in two case con-
trol studies in 28 and 32 preterm infants, respectively (Corvaglia
2011; Corvaglia 2011a), and in a pH probe cohort study in 50
preterm infants (Atasay 2010). However, there was no effect on
non-acid GOR. The impact of alginate in reducing symptoms of
GOR in preterm infants is unclear. Corvaglia 2011 found that
alginate did not reduce the frequency of GOR-related apnoea,
while Atasay 2010 found improvement in vomiting and weight
gain. Corvaglia 2012, a case control study of 28 preterm infants,
found that specially designed preterm formula thickened with the
digestible carbohydrate amylopectin reduced the number of acid
GOR episodes without improving the crucial acid oesophageal
exposure and non-acid GOR detected by pH-MII. In Corvaglia
2006, a case control study of 5 preterm infants, starch-thickened
expressed human breast milk showed no effect on number of acid
and non-acid GOR episodes detected by pH-MII.
The findings of this review may also not be applicable to infants
with GOR due to neurological impairment or other medical rea-
sons, such as cow’s milk intolerance. The use of feed thickeners
such as alginates in breastfeeding infants, including their efficacy
and impact on breastfeeding rates, have also not been fully inves-
tigated in trials to date. This is crucial, as the prevalence of GOR
in breastfeeding infants is similar to bottle-feeding infants (Barak
2006).
Apart fromdiarrhoea reported in one study (Iacono 2002), thema-
jority of studies reported no significant differences in side effects
between the control and feed thickener groups.However, the stud-
ies were mainly short term, with follow-up periods of up to eight
weeks, and were not powered to detect side effects. Hence, small
but real differences in adverse effects may not be found without a
large-scale randomised controlled trial or observational study. In
addition, some reports excluded infants who had side effects from
the analysis.
The long-term impact of excessive weight gain in feed thickener
groups noted in some studies is unclear, especially with the use of
non-standard thickened formula when feed thickeners are added
to a standard formula at home (Chao 2007; Hegar 2008; Moya
1999; Xinias 2005). This may provide an excessively high caloric
density. However, there is increasing evidence that infants regulate
the volume of intake depending on calorie density, although the
excessive calories added due to feed thickeners are mostly in the
form of carbohydrates, and the risk of high-carbohydrate but low-
protein feeding remains even when the infant self regulates (Agosti
2003; Atkinson 2004; Carver 2001; Cooke 2001). The allergenic-
ity of commercially available thickening agents is also uncertain
to date, although none of the studies reported any such events.
The severity of GOR is usually dependent on the frequency and
volume of regurgitation or vomiting, or both. Although our meta-
analyses show that feed thickeners reduced the frequency of re-
gurgitation or vomiting, the impact on volume or severity of the
events is unclear due to the lack of standardisation in how these
variables were reported in the four included studies that reported
volume or severity of regurgitation (Iacono 2002; Miller 1999;
Vandenplas 1994; Vanderhoof 2003).
Potential biases in the review process
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The methodological quality of the included studies varied (Figure
2). The included studies depended on parental report of signs
or symptoms. Despite attempts to blind the parents or caregivers
from the intervention, and the fact that thickened formula mainly
thickens only when it comes in contact with acid in the stomach,
it was likely that parents may still have noted the higher viscosity
of the thickened formula compared to control unthickened feeds.
This could potentially lead to overestimation of the reduction in
frequency of regurgitation or vomiting and the incidence of side
effects in the feed thickener group. However, this lack of blinding
may be inevitable in such studies.
We assessed the randomisation or allocation concealment method
as at unclear or high risk of bias in five of the eight included studies.
This may have introduced selection bias in our analysis. There
was an imbalance in the baseline characteristics of infants in the
feed thickener and control groups in four studies. In three trials
infants in the intervention group had a higher number of vomiting
episodes per day or larger measures of regurgitation volume than
infants in the control group (Miller 1999; Vanderhoof 2003;
Xinias 2005). Infants in the intervention group in the Moya
1999 study were older than those in the control group. These
imbalances may have resulted in an overestimation of the effects
of the intervention, as infants in the former three studies had
more severe symptoms that were likely to respond better to feed
thickeners, while older infants in the latter study were more likely
to recover from regurgitation due to spontaneous resolution of the
condition with age.
Three studies declared receiving funding from a pharmaceutical
company (Miller 1999; Vanderhoof 2003; Xinias 2005). We did
not assess publication bias in our analysis as there were fewer than
10 included studies. Given these limitations, the strength of the
evidence presented must be interpreted with caution.
Agreements and disagreements with other
studies or reviews
Similiar to four previous reviews (Carroll 2002; Craig 2004;
Horvath 2008; Neu 2012), our review found moderate-certainty
evidence that feed thickeners reduce the frequency of regurgita-
tion or vomiting per day in formula-feeding term infants up to six
months of age presenting with uncomplicated GOR. Although
only the cornstarch- and alginate-thickened groups showed a
significant reduction in frequency of regurgitation or vomiting
(Figure 3; Figure 4), the evidence in our current analysis was in-
sufficient to conclude that one form of feed thickener is superior
to another, which is in concordance with previous reviews. How-
ever, unlike in previous reviews, we found that feed thickeners also
improved pH probe study parameters of reflux index (measure of
oesophageal acid exposure), number of acid reflux episodes over 5
minutes, and duration of longest acid reflux episode, but noted no
difference in number of acid reflux episodes per hour. However,
the strength of evidence for this is low, as only two included studies
reported pH probe study parameters.
Neu 2012 (search date 2002 to 2011) reviewed the literature for
full-text articles in the English language on non-surgical treat-
ment for symptoms of irritability in infants with GORD up to
23 months of age. Cross-over trials were included in the review.
The review found three studies, and the authors concluded that
infants treated with rice- and corn-thickened formula had more
reduction in irritability and reflux than the control group.
Horvath 2008 (search date up to May 2008) found that feed
thickeners were moderately effective in treating GOR in healthy
infants based on 14 included studies recruiting 877 infants. The
review included cross-over trials and infants up to two years of
age. The authors found that feed thickener improved regurgitation
or vomiting and weight gain symptoms with no serious adverse
effects being reported.However, apart from the duration of longest
acid reflux episode, they did not find improvement in pH probe
study parameters, including the reflux index. They also found no
definitive evidence showing that one particular feed thickener is
more effective than another.
Craig 2004 (search date up to January 2003) concluded that feed
thickeners reduced the frequency and severity of regurgitation of
developmentally normal children aged between 1 month and 2
years based on 8 studies recruiting 419 infants. There was no
difference in reflux index obtained from pH probe parameter.
Carroll 2002 (search date up to November 2000) found that feed
thickeners reduced vomiting symptoms without reducing measur-
able reflux based on 4 studies recruiting 188 infants.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Gastro-oesophageal reflux (GOR) is a physiological self resolving
phenomenon in infants that does not necessarily require any treat-
ment. However, GOR becomes pathological when it causes com-
plications or troublesome symptoms. The aim of management of
gastro-oesophageal reflux disease (GORD) should be to reduce
symptoms and prevent complications while maintaining normal
growth without side effects of the treatment. However, this dis-
tinction between GOR and GORD may be unclear at times. Fre-
quent regurgitation is a common cause of parental anxiety and
referral for specialist input. The cornerstone in the management
of uncomplicated GOR should be parental education and reassur-
ance with modification of feeding frequency and volume if nec-
essary. However, if regurgitation symptoms persist in term bottle-
feeding infants, feed thickeners may be considered, as they have
been found to reduce the frequency of regurgitation or vomiting
by two episodes per day when compared to control treatment. The
reduction by two episodes of regurgitation or vomiting per day
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may be of clinical significance to parents or caregivers. This ther-
apeutic benefit of feed thickener was reproducible after removing
studies with high risk of bias from our analysis. However, the im-
provement in pH probe parameters, especially reflux index, with
feed thickeners should be interpreted with caution as there was
very limited evidence available.
Due to the small number of studies available, our analysis pro-
vided insufficient information to conclude whether one type of
feed thickener is superior to another. However, it may be prudent
to use feed thickeners that have undergone clinical evaluation. Al-
though alginate can be used in breastfeeding infants, so far there
is insufficient evidence to show its effectiveness and impact on
breastfeeding infants. There is also insufficient evidence to rec-
ommend the use of feed thickeners including alginate in preterm
infants, as well as reported side effects that include necrotising en-
terocolitis (Beal 2012; Clarke 2004).
Implications for research
Despite the widespread use of feed thickeners such as alginates in
neonatal units (Dhillon 2004), there is a lack of evidence for the
use of feed thickeners in preterm infants. The results of this review
suggest that a randomised controlled trial should be carried out
in preterm infants up to 44 weeks corrected age to investigate the
role of feed thickeners in the treatment of GORD. A randomised
controlled trial design is crucial for investigating the efficacy of any
treatment for GOR, as it is well accepted that the condition im-
proves and resolves spontaneously as the infant grows. Compari-
sonwith a parallel control group, selected by appropriate randomi-
sation, is essential to differentiate the natural progression of the
disease from the effect of the intervention. In addition, concerns
about serious side effects such as necrotising enterocolitis warrant
that there should be a strict safety reporting mechanism, and the
intervention should be started only after infants are tolerating full
enteral feeds. Feed thickeners should be specially designed to meet
the nutritional demands of preterm infants. Such a study should
consider objective outcomes such as pH probe study or combined
pH and impedence measures, as well as clinical outcomes such
as regurgitation frequency and severity, GOR-related apnoeas and
desaturations, and growth to provide clinically relevant conclu-
sions.
For term infants, further parallel-group randomised controlled tri-
als exploring the effect of different types of feed thickeners would
be informative. Comparison with an appropriate control must
be included to differentiate between the natural progression of
the disease and the effect of the intervention. Although parental
reporting of symptoms of GOR may be affected by incomplete
blinding, it should still be reported alongside objective measure-
ments such as pH probe study or combined pH and impedence
monitoring, as the reported outcomes are more relevant for clin-
ical practice. The use of a validated regurgitation scoring system
such as the Infant Gastroesophageal Reflux Questionnaire Revised
(I-GERQ-R) or the Vandenplas scoring system should be consid-
ered to enable comparability between studies (Kleinman 2006;
Orenstein 2010; Vandenplas 1994).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chao 2007
Methods Study design: Randomised controlled trial.
Study grouping: Parallel group.
Participants Baseline characteristics
Control/placebo
• Total number of infants randomised: 40.
• Age (mean ± 1 standard deviation): 90.5 ± 27.4 days.
• Sex: 53% male.
• Number of episodes of regurgitation/vomiting per day (mean ±1 standard deviation):
4.15 ± 1.68.
• Volume of formula intake (mean ± 1 standard deviation): 84.1 ± 22.6 mL/feed.
Feed thickener
• Total number of infants randomised: 41.
• Age (mean ± 1 standard deviation): 90.2 ± 26.9 days.
• Sex: 51% male.
• Number of episodes of regurgitation/vomiting per day (mean ±1 standard deviation):
4.19 ± 1.71.
• Volume of formula intake (mean ±1 standard deviation): 83.6 ± 22.3 mL/feed.
Inclusion criteria:Non-breastfed infants (age 2 to 4 months) presenting with 3 or more
episodes of regurgitation/vomiting per day
Exclusion criteria:Mechanical obstruction such as infantile hypertrophic pyloric steno-
sis and malrotation were excluded with an upper gastrointestinal barium study before
inclusion. Infants with atopic symptoms such as eczema, watery rhinorrhoea, or diar-
rhoea suspecting of cow’s milk allergy were excluded
Pretreatment: There was no difference in demographics and baseline clinical character-
istics between intervention and control groups
Study period: 2 years (July 2002 to July 2004).
Interventions Intervention characteristics
Control/placebo
• Type of control: 25% strengthened regular infant formula (Novalac 1, Paris,
France). 5 measurements of formula (instead of the recommended 4) were added to
120 mL of water.
• Duration of intervention: 8 weeks.
• Co-intervention: Not mentioned.
• Others: Whey:casein ratio of 60:40.
Feed thickener
• Type of feed thickener: Cornstarch-thickened antiregurgitation formula (Novalac
AR, Paris, France).
• Duration of intervention: 8 weeks.
• Co-intervention: Not mentioned.
• Others: Whey:casein ratio of 20:80.
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Chao 2007 (Continued)
Outcomes Outcomes were reported after 8 weeks of intervention.
Number of episodes of regurgitation, posseting, or vomiting per day
• Outcome type: Continuous outcome.
• Reporting: Fully reported.
• Data value: Endpoint score was used. There was insufficient information in the
paper to obtain change from baseline score.
Sleep disturbance
• Outcome type: Dichotomous outcome as proportion of infants with sleep
disturbance at the end of intervention period.
• Reporting: Fully reported.
• Data value: Endpoint score was used.
Irritability
• Outcome type: Dichotomous outcome as proportion of infants with irritability
at the end of intervention period.
• Reporting: Fully reported.
• Data value: Endpoint score was used.
Cough
• Outcome type: Dichotomous outcome as proportion of infants with cough at the
end of intervention period.
• Reporting: Fully reported.
• Data value: Endpoint score was used.
Diarrhoea
• Outcome type: Dichotomous outcome as proportion of infants with diarrhoea at
the end of intervention period.
• Reporting: Partially reported.
• Data value: Endpoint score was used.
• Notes: 8 infants who developed marked diarrhoea or enteritis were excluded from
the study. There was no mention of the proportion of the 8 infants in the control or
intervention group.
Notes Sponsorship source: None declared.
Country: Taiwan.
Setting: Outpatients.
Author name: Yvan Vandenplas.
Institution: Universitair Ziekenhuis Brussel Kinderen.
Email: yvan.vandenplas@uzbrussel.be
Address:Department of Pediatrics, Universitair Ziekenhuis Brussel Kinderen, Vrije Uni-
versiteit Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisationwas performedusing an en-
velope-drawing system.However, therewas
no mention of how the random numbers
were generated
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Allocation concealment (selection bias) Low risk Randomisationwas performedusing an en-
velope-drawing system
Blinding of participants and personnel
(performance bias)
Symptoms or signs of gastro-oesophageal
reflux and side effect
High risk Blinding of intervention (cornstarch-thick-
ened AR formula) and control (25%
strengthened regular infant formula) were
unlikely. Frequency of symptomsdepended
on parental report
Blinding of participants and personnel
(performance bias)
Oesophageal pH probe study parameter
Low risk Not applicable.
Blinding of outcome assessment (detection
bias)
Symptoms or signs of gastro-oesophageal
reflux and side effects
High risk Blinding of intervention (cornstarch-thick-
ened antiregurgitation formula) and con-
trol (25% strengthened regular infant for-
mula) were unlikely. Frequency of symp-
toms depended on parental report
Blinding of outcome assessment (detection
bias)
Oesophageal pH probe study parameter
Low risk Not applicable
Incomplete outcome data (attrition bias)
All outcomes
High risk Of 100 included infants, 81 infants com-
pleted the 2-month clinical follow-up.
Of the 19 excluded infants, 8 developed
marked diarrhoea or enteritis, 5 experi-
enced upper respiratory infection, and 6
did not have regular follow-up. The pro-
portion of these infants in the feed thick-
ener and control group was not specified
Selective reporting (reporting bias) Unclear risk All outcomes mentioned in the methods
section of the study were reported, but the
study protocol or trial registration numbers
were not available
Other bias Low risk There was no difference in the demograph-
ics and baseline clinical characteristics be-
tween the intervention and control group
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Hegar 2008
Methods Study design: Randomised controlled trial.
Study grouping: Parallel group.
Participants Baseline characteristics
Control/placebo
• Total number of infants randomised: 20.
• Age (mean ± 1 standard deviation): 47.1 ± 17.7 days.
• Sex: 30% male.
• Number of episodes of regurgitation/vomiting per day (mean ±1 standard deviation):
5.9 ± 1.7.
• Volume of formula intake (mean ±1 standard deviation): 123.9 ± 47.9 mL/kg/day.
Feed thickener 1
• Total number of infants randomised: 20.
• Age (mean ± 1 standard deviation): 48.7 ± 15.8 days.
• Sex: 45% male.
• Number of episodes of regurgitation/vomiting per day (mean ± 1 standard deviation):
5.7 ± 1.9.
• Volume of formula intake (mean ± 1 standard deviation): 130.8 ± 47.2 mL/kg/day.
Feed thickener 2
• Total number of infants randomised: 20.
• Age (mean ± 1 standard deviation): 46.2 ± 13.1 days.
• Sex: 35% male.
• Number of episodes of regurgitation/vomiting per day (mean ± 1 standard deviation):
5.5 ± 1.8.
• Volume of formula intake (mean ± 1 standard deviation): 115.9 ± 48.2 mL/kg/day.
Inclusion criteria:Healthy term-born, formula-fed infants (age 1 to 3 months) present-
ing with frequent regurgitation or vomiting, or both (4 times/day since at least 1 week
before inclusion). All of the infants were exclusively fed with standard infant formula at
normal concentration at baseline
Exclusion criteria:
• Mechanical obstruction such as infantile hypertrophic pyloric stenosis and
malrotation.
• Atopic symptoms such as eczema, watery rhinorrhoea, or diarrhoea (suspected
cow’s milk allergy).
• Congenital abnormalities.
• Feeding refusal, haematemesis, melena.
• Use of antireflux medication or previous use of thickened formula.
Pretreatment: No baseline characteristics were statistically significant.
Study period: Not reported.
Interventions Intervention characteristics
Control/placebo
• Type of control: Standard infant formula.
• Duration of intervention: 4 weeks.
• Co-intervention: Parental reassurance and explanation.
• Compliance: No issue reported.
• Others: Energy 63.0 to 66.7 calories/100 mL; protein 1.5 to 1.66 g/100 mL;
casein/lactalbumin ratio 30:70.
Feed thickener 1
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Hegar 2008 (Continued)
• Type of feed thickener: Standard infant formula thickened with rice cereal.
• Dosage of thickener used: Standard formula thickened with 5 g rice cereal (Rice
Cereal, Nestlé, Vevey, Switzerland) per 100 mL.
• Duration of intervention: 4 weeks.
• Co-intervention: Parental reassurance and explanation.
• Compliance: No issue reported.
• Others: Energy 83.6 to 87.3 calories/100 mL; protein 2.25 to 2.41 g/100 mL;
casein/lactalbumin ratio 30:70.
Feed thickener 2
• Type of feed thickener or control: Carob bean gum.
• Dosage of thickener used: Antiregurgitation formula manufactured with bean gum
as a thickening agent (Nutrilon1-AR, Royal Numico, Zoetermeer, the Netherlands).
• Duration of intervention: 4 weeks.
• Co-intervention: Parental reassurance and explanation.
• Compliance: No issue reported.
• Others: Energy 70 calories/100 mL; protein 1.75 g/100 mL; casein/lactalbumin
ratio 80:20.
Outcomes Outcomes were reported after 4 weeks of intervention.
Number of episodes of regurgitation, posseting, or vomiting per day
• Outcome type: Continuous outcome.
• Reporting: Partially reported.
• Data value: Change from baseline score was used.
• Notes: P value for the mean difference between the pre- and postintervention
score was used to obtain the standard deviation for change of baseline scores in the rice
cereal group.
Sleep disturbance
• Outcome type: Dichotomous outcome.
• Reporting: Partially reported.
• Data value: Endpoint score was used.
• Notes: There was no difference in sleeping disturbance (information from author)
.
Diarrhoea
• Outcome type: Dichotomous outcome.
• Reporting: Partially reported.
• Data value: Endpoint score was used.
• Notes: Stool characteristics (consistency, frequency) did not differ between groups
during the intervention period; the majority of infants had normal soft stools.
Notes Sponsorship source: None.
Country: Belgium.
Setting: Not specified but likely outpatient.
Author name: Yvan Vandenplas.
Institution: Universitair Ziekenhuis Brussel Kinderen.
Email: yvan.vandenplas@uzbrussel.be
Address:Department of Pediatrics, Universitair Ziekenhuis Brussel Kinderen, Vrije Uni-
versiteit Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
Risk of bias
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Hegar 2008 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed according
to an automated randomisation
Allocation concealment (selection bias) Unclear risk Method of allocation concealment was not
described.
Blinding of participants and personnel
(performance bias)
Symptoms or signs of gastro-oesophageal
reflux and side effect
High risk Parentswere blinded to the formulae.How-
ever, parents were likely to observe that the
thickened formula had a higher viscosity,
which could affect parent-reported symp-
toms or signs of gastro-oesophageal reflux
and side effect
Blinding of participants and personnel
(performance bias)
Oesophageal pH probe study parameter
Low risk Not applicable
Blinding of outcome assessment (detection
bias)
Symptoms or signs of gastro-oesophageal
reflux and side effects
High risk Parentswere blinded to the formulae.How-
ever, parents were likely to observe that the
thickened formula had a higher viscosity,
which could affect parent-reported symp-
toms or signs of gastro-oesophageal reflux
and side effect
Blinding of outcome assessment (detection
bias)
Oesophageal pH probe study parameter
Low risk Not applicable
Incomplete outcome data (attrition bias)
All outcomes
Low risk All 60 included infants completed the study
and were accounted for
Selective reporting (reporting bias) Unclear risk All outcomes mentioned in the methods
section of the study were reported, but the
study protocol or trial registration numbers
were not available
Other bias Low risk No statistically significant difference be-
tween intervention and control groups at
baseline
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Iacono 2002
Methods Study design: Randomised controlled trial.
Study grouping: Parallel group.
Participants Baseline characteristics
Control/placebo
• Total number of infants randomised: 84.
• Age (median): 45 days.
• Sex: 51% male.
Intervention
• Total number of infants randomised: 82.
• Age (median): 45 days.
• Sex: 55% male.
Inclusion criteria: Bottle-fed infants, under 4 months of age, who consecutively pre-
sented at the outpatient clinics of 6 paediatric centres with frequent regurgitation/vom-
iting due to uncomplicated GOR
Exclusion criteria: Patients over 4 months, breast- or mixed-feeding, signs of “compli-
cated” GOR, GOR secondary to food allergy
Pretreatment: No difference in regurgitation score at baseline.
Study period: Not reported.
Interventions Intervention characteristics
Control/placebo
• Type of control: Standard formula with a similar composition to that of the
thickened formula, without any thickening component (Humana Plus, Humana,
Milan, Italy).
• Duration of intervention: 8 weeks.
• Co-intervention: None.
Intrevention
• Type of feed thickener or control: Antiregurgitation formula thickened with carob
bean gum (Humana AR 1, Humana, Milan, Italy).
• Duration of intervention: 8 weeks.
• Co-intervention: None.
Outcomes Outcomes were reported after 8 weeks of intervention.
Number of infants without regurgitation, posseting, or vomiting at the end of the intervention
period
• Outcome type: Dichotomous outcome as proportion of infants without
regurgitation at the end of intervention period.
• Reporting: Fully reported.
• Data value: Endpoint score was used.
Diarrhoea
• Outcome type: Dichotomous outcome as proportion of infants with diarrhoea at
the end of intervention period.
• Reporting: Partially reported.
• Data value: Endpoint value was used.
• Notes: Treatment of 14 infants in the thickened-formula group was suspended
due to the onset of diarrhoea during the first 2 weeks of the study.
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Notes Comments: Published as correspondence to the editor only. We obtained further infor-
mation from the author
Sponsorship source: None declared.
Country: Italy.
Setting: Children’s outpatient clinics in 6 centres.
Comments:
Author name: Giuseppe Iacono.
Institution: Pediatric Gastroenterology, “Di Cristina” Hospital.
Email: stoai@inwind.it
Address: Pediatric Gastroenterology, “Di Cristina” Hospital, Palermo, Italy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Although the correspondence stated that
infants were randomly assigned to 2 treat-
ment regimens, the method of randomisa-
tion was not described
Allocation concealment (selection bias) Unclear risk Themethod of allocation concealment was
not described.
Blinding of participants and personnel
(performance bias)
Symptoms or signs of gastro-oesophageal
reflux and side effect
High risk Method of blinding was not described.
However, parents were likely to note the
higher viscosity of the thickened feed,
which could have affected parental report
of signs and symptoms
Blinding of participants and personnel
(performance bias)
Oesophageal pH probe study parameter
Low risk Not applicable
Blinding of outcome assessment (detection
bias)
Symptoms or signs of gastro-oesophageal
reflux and side effects
High risk Method of blinding was not described.
However, parents were likely to note the
higher viscosity of the thickened feed,
which could have affected parental report
of signs and symptoms
Blinding of outcome assessment (detection
bias)
Oesophageal pH probe study parameter
Low risk Not applicable
Incomplete outcome data (attrition bias)
All outcomes
Low risk Author did not mention the number of
infants excluded prior to randomisation.
However, all randomised infants were in-
cluded in the final analysis
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Iacono 2002 (Continued)
Selective reporting (reporting bias) High risk This study was published as a correspon-
dence to the editor only. Not all values for
themeasured outcomewere reported. Base-
line characteristics of infants pre-interven-
tion were not reported. Study protocol or
trial registration numbers were not avail-
able
Other bias Low risk The intergroup comparison of the data
did not show any difference in regurgita-
tion score between the group receiving the
thickened formula and the control group
at baseline
Miller 1999
Methods Study design: Randomised controlled trial.
Study grouping: Parallel group.
Participants Baseline characteristics
Control/placebo
• Total number of infants randomised: 48.
• Age (mean ±1 standard deviation): 4.1 ± 0.39 months.
• Sex: 54% male.
• Race/ethnicity: 98% white.
• Number of episodes of regurgitation/vomiting per day (median (range)): 7 (2 to 36).
Feed thickener
• Total number of infants randomised: 42.
• Age (mean ±1 standard deviation): 3.9 ± 0.4 months.
• Sex: 67% male.
• Race/ethnicity: 95% white.
• Number of episodes of regurgitation/vomiting per day (median (range)): 8.5 (2 to 50).
Inclusion criteria: Paediatric patients aged between 0 and 12 months at the pretreat-
ment assessment, with symptoms consistent with gastro-oesophageal reflux (persistent,
unmanageable vomiting/regurgitation or vomiting/regurgitation at least twice daily for
the 2 days prior to the start of the study)
Exclusion criteria: Infants were excluded from the study if they had known or suspected
oesophageaI disease, significant gastrointestinal disease, or uncontrolled neurological,
cardiac, respiratory, metabolic, hepatic disease or renal impairment; were likely to expe-
rience excessive water loss (e.g. fever, diarrhoea); had not yet completed the 37th week
of development or weighed less than 2.5 kg; were receiving drugs likely to cause sodium
retention; had previously participated in the present study or were currently participating
in any other clinical study or had suspected or known sensitivity to alginates
Pretreatment: Patient demographics were similar with respect to age, gender, weight,
and ethnic origin between the 2 study groups. 22% of infants had a pre-existing medical
condition upon entry into the study that was comparable between groups. The nature
of this condition was not reported
The duration of vomiting/regurgitation was comparable between the 2 treatment groups
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However, the number of vomiting/regurgitation episodes in the 24-hour period prior to
the pretreatment assessmentwas slightly higher in the alginate group (8.5 vs 7 episodes per
day), and the number of episodes was not evenly distributed between sex and treatment
groups
Study period: 18 months (April 1994 to October 1995).
Interventions Intervention characteristics
Control/placebo
• Type of control: Placebo.
• Dosage: Infants weighing < 4.54 kg were given 1 sachet of placebo. Infants
weighing ≥ 4.54 kg were given 2 sachets of placebo.
• Duration of intervention: 2 weeks.
• Co-intervention: None.
• Number of withdrawals: 13 (7 due to adverse events, 3 due to lack of efficacy, 3 no
reason provided).
• 2 infants did not receive the study medication and were excluded from the
analysis.
• Compliance: 59%.
Feed thickener
• Type of feed thickener: Alginate.
• Dosage: Infants weighing < 4.54 kg were given 1 sachet of alginate. Infants
weighing ≥ 4.54 kg were given 2 sachets of alginate. Each sachet of alginate contained
sodium alginate (225 mg) and magnesium alginate (87.5 mg) in a total of 0.65 g.
• Duration of intervention: 2 weeks.
• Co-intervention: None.
• Number of withdrawals: 7 (4 due to adverse events, 2 due to lack of efficacy, 1 no
reason provided).
• Compliance: 71%.
Outcomes Outcomes were reported after 2 weeks of intervention.
Number of episodes of regurgitation, posseting, or vomiting per day
• Outcome type: Continuous outcome.
• Reporting: Partially reported.
• Data value: Change from baseline score was used.
• Notes: Median and range of number of episodes of regurgitation per day over last
24 hours were reported. No mean or standard deviation was reported. We contacted
the author but the data were not available. As the sample size was above 25, we assume
that mean was equivalent to median. We used P value for the difference in median
number of episodes of regurgitation per day between placebo and alginate group to
obtain the standard deviation.
Diarrhoea
• Outcome type: Dichotomous outcome as proportion of infants with diarrhoea at
the end of intervention period.
• Reporting: Fully reported.
• Data value: Endpoint value was used.
Colic
• Outcome type: Dichotomous outcome as proportion of infants with colic at the
end of intervention period.
• Reporting: Fully reported.
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• Data value: Endpoint value was used.
Respiratory symptom (acute nasopharyngitis)
• Outcome type: Dichotomous outcome as proportion of infants with acute
nasopharyngitis at the end of intervention period.
• Reporting: Fully reported.
• Data value: Endpoint value was used.
Constipation (bowel obstruction)
• Outcome type: Dichotomous outcome as proportion of infants with constipation
at the end of intervention period.
• Reporting: Fully reported.
• Data value: Endpoint value was used.
Notes Comments: The study included infants up to 12 months of age. The author was con-
tacted and did not have the actual age ranges of infants recruited in the study. However,
the reported mean age and standard deviation of infants recruited in the study was 4 ±
0.4 months. Based upon these values, we decided to include the study, as the spread of
infants was likely to be between 3 to 5 months
2 infants were excluded from the analysis of the placebo group as they did not receive
the placebo
Sponsorship source: Parexel International Ltd and Reckitt 6 Colman Products Ltd for
funding the study
Country: UK.
Setting: 25 general practice centres in the UK.
Author name: Dr S. Miller.
Institution: The New Surgery.
Email: thenewsurgeryW12@nhs.net
Address: 143a Uxbridge Road, Shepherds Bush, London W12.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The paper stated that the study was ran-
domised, but did not mention how ran-
domisation was performed
Allocation concealment (selection bias) Unclear risk Nomentionof howallocation concealment
was performed
Blinding of participants and personnel
(performance bias)
Symptoms or signs of gastro-oesophageal
reflux and side effect
Low risk This was a double-blind trial with match-
ing placebo administered
Blinding of participants and personnel
(performance bias)
Oesophageal pH probe study parameter
Low risk Not applicable
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Blinding of outcome assessment (detection
bias)
Symptoms or signs of gastro-oesophageal
reflux and side effects
Low risk This was a double-blind trial with match-
ing placebo administered
Blinding of outcome assessment (detection
bias)
Oesophageal pH probe study parameter
Low risk Not applicable
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 infants were excluded from the analysis
of the placebo group as they did not receive
the placebo. A further 20 infants withdrew
from the study (7 in the alginate group and
13 in the placebo group). However, they
were all included in the final analyses as
per the intention-to-treat protocol. Results
from the efficacy evaluable populationwere
similar to those from the intention-to-treat
protocol
Selective reporting (reporting bias) Unclear risk All outcome measures described in the
methods section were reported. However,
study protocol or trial registration number,
or both, were not available
Other bias High risk The study was funded by Parexel Interna-
tional Ltd and Reckitt 6 Colman Products
Ltd
Infants in the alginate group had a higher
number of vomiting/regurgitation episodes
per day at baseline as compared to the
placebo group
Moya 1999
Methods Study design: Randomised controlled trial.
Study grouping: Parallel group.
Participants Baseline characteristics
Control/placebo
• Total number of infants randomised: 6.
• Age (mean ± 1 standard deviation): 54.5 ± 16.8 days.
• Number of episodes of regurgitation/vomiting per day (mean ±1 standard deviation):
10.6 ± 2.5.
• Volume of formula intake (mean ±1 standard deviation): 150.9 ± 24.3 mL/kg/day.
Feed thickener 1
• Total number of infants randomised: 8.
• Age (mean ±1 standard deviation): Not reported.
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• Number of episodes of regurgitation/vomiting per day (mean ±1 standard deviation):
8.9 ± 3.6.
• Volume of formula intake (mean ± 1 standard deviation): 148.4 ± 27.9 mL/kg/day.
Feed thickener 2
• Total number of infants randomised: 6.
• Age (mean ±1 standard deviation): 82.2 ± 24.4 days.
• Number of episodes of regurgitation/vomiting per day (mean ±1 standard deviation):
10.2 ± 1.5.
• Volume of formula intake (mean ±1 standard deviation): 156.4 ± 23.8 mL/kg/day.
Inclusion criteria: Infants under 4 months of age (1 to 4 months old) with frequent re-
gurgitations (more than 5 regurgitations per day) without any signs of gastro-oesophageal
reflux disease were included
Exclusion criteria: Preterm, low birth weight, breastfeeding infants, infants with history
of previous illness, or infants who had received any antireflux medication were excluded
Pretreatment: The baseline clinical characteristics of infants were similar between the
groups, except for the age of infant at entry to the study between infants in the control
group (group 1) and infants in the group receiving carob bean gum-thickened formula
(group 3). Infants in group 1 were younger at entry to the study, at 54.5 days (standard
deviation 16.8 days), as compared to 82.2 days (standard deviation 24.4 days) in group
3
Study period: Not reported.
Interventions Intervention characteristics
Control/placebo
• Type of control: Standard formula.
• Duration of intervention: 2 weeks.
• Co-intervention: Adjustment of amount and frequency of feed according to age
and weight as well as parental explanation/reassurance.
Feed thickener 1
• Type of feed thickener: Formula thickened with cornstarch.
• Duration of intervention: 2 weeks.
• Co-intervention: Adjustment of amount and frequency of feed according to age
and weight as well as parental explanation/reassurance.
Feed thickener 2
• Type of feed thickener: Formula thickened with carob bean gum.
• Duration of intervention: 2 weeks.
• Co-intervention: Adjustment of amount and frequency of feed according to age
and weight as well as parental explanation/reassurance.
Outcomes Outcomes were reported after 2 weeks of intervention.
Number of episodes of regurgitation, posseting, vomiting, or haematemesis per day
• Outcome type: Continuous outcome.
• Reporting: Fully reported.
• Unit of measure: Number of episodes/day.
• Direction: Lower is better.
• Data value: Change from baseline.
• Notes: Number of regurgitation episodes at end of study compared to number of
regurgitation episodes at the start of study. No standard deviation given, but P value
provided at < 0.01 for control, P < 0.001 for thickener 1, and P < 0.005 for thickener 2.
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Diarrhoea
• Outcome type: Dichotomous outcome.
• Reporting: Partially reported.
• Unit of measure: Number per day.
• Direction: Lower is better.
• Data value: Change from baseline.
• Notes: The author reports no undesirable effects detected in any of the infants
studied. No standard deviation given for mean difference. P values provided as < 0.01
in control, < 0.002 in thickener 1, and not significant in thickener 2. Slight
discrepancy between data in table and text. Data in table used.
Notes Comments: Published in Spanish.
Sponsorship source: None mentioned.
Country: Spain.
Setting: Outpatients.
Author name: M Juste.
Institution: Universidad Miguel Hernandez.
Email: Manuel.Moya@umh.es
Address: Servicio de Pediatria, Hospital Universitario San Juan, Universidad Miguel
Hernandez, Ctra. Nacional 332, Alicante-Valencia, s/n 03550 San Juan de Alicante
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was carried out by the hos-
pital pharmacy, which was not involved in
the trial (information from author)
Allocation concealment (selection bias) Low risk Allocation was concealed using signed,
sealed envelope (information from author)
Blinding of participants and personnel
(performance bias)
Symptoms or signs of gastro-oesophageal
reflux and side effect
High risk Initials ’AR’ appear on the label depend-
ing on the type of formula infant received.
Parents may notice the higher viscosity of
the antiregurgitation formula, which could
affect parental report of signs or symptoms
Blinding of participants and personnel
(performance bias)
Oesophageal pH probe study parameter
Low risk Not applicable
Blinding of outcome assessment (detection
bias)
Symptoms or signs of gastro-oesophageal
reflux and side effects
High risk Parents may notice the higher viscosity of
the antiregurgitation formula, which could
affect parental report of signs or symptoms
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Blinding of outcome assessment (detection
bias)
Oesophageal pH probe study parameter
Low risk Not applicable
Incomplete outcome data (attrition bias)
All outcomes
Low risk All infants were followed up until the end
of the 2-week study period (information
from author)
Selective reporting (reporting bias) Unclear risk All outcome measures described in the
methods section were reported. However,
the study protocol or trial registrationnum-
ber, or both, were not available
Other bias High risk Infants in the control group were younger
on entry to the study than those in the in-
tervention group. This could have resulted
in an overestimation of the effect of the
intervention, as gastro-oesophageal reflux
normally resolves with time
Vandenplas 1994
Methods Study design: Quasi-randomised controlled trial.
Study grouping: Parallel group.
Participants Baseline characteristics
Control/placebo
• Total number of infants randomised: 10.
• Age (range): 7 to 120 days.
Feed thickener
• Total number of infants randomised: 10.
• Age (range): 7 to 120 days.
Inclusion criteria:Term formulamilk-feeding infants between1week and4months old,
presenting with more than 5 episodes of regurgitations a day and abnormal oesophageal
pH monitoring results with percentage of time with pH < 4.0 between 10% and 30%
Exclusion criteria: Infants with secondary gastro-oesophageal reflux caused by urinary
or gastrointestinal infection and food allergy were excluded using appropriate cultures,
immunoglobulin E, radioallergosorbent test (cow’s milk, betalactoglobulin, lactalbumin,
casein), and skin prick test for cow’s milk. Infants who were not thriving or had symp-
toms suggestive of peptic oesophagitis were excluded. If there was any suspicion, upper
gastrointestinal endoscopy with multiple biopsies was performed
Pretreatment: There was no difference in participant characteristics between interven-
tion and control group at baseline
Study period: Not reported.
Interventions Intervention characteristics
Control/placebo
• Type of control: Standard formula.
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• Duration of intervention: 1 week.
• Co-intervention: Parental reassurance and positional treatment.
Feed thickener
• Type of control: Antiregurgitation formula containing Saint John’s bread (carob
bean gum).
• Duration of intervention: 1 week.
• Co-intervention: Parental reassurance and positional treatment.
Outcomes Outcomes were reported after 1 week of intervention.
Number of infants without regurgitation, posseting, or vomiting at the end of the intervention
period
• Outcome type: Dichotomous outcome as proportion of infants without
regurgitation at the end of intervention period.
• Reporting: Fully reported.
• Data value: Endpoint score was used.
• Notes: Number of infants without regurgitation was obtained from a grade of
severity of regurgitations of 0.
Reflux index
• Outcome type: Continuous outcome.
• Reporting: Partially reported.
• Unit of measure: Precentage change.
• Data value: Change from baseline score was used.
• Notes: Standard deviations for change of baseline scores were not reported. They
were obtained using the reported P value for change of baseline scores for control and
intervention groups respectively.
Duration of longest episode
• Outcome type: Continuous outcome.
• Reporting: Partially reported.
• Unit of measure: Minutes.
• Data value: Change from baseline score was used.
• Notes: Standard deviations for change of baseline scores were not reported. They
were obtained using the reported P value for change of baseline scores for control and
intervention groups respectively.
Number of reflux episodes lasting > 5 minutes
• Outcome type: Continuous outcome.
• Reporting: Partially reported.
• Data value: Change from baseline score was used.
• Notes: Standard deviations for change of baseline scores were not reported. They
were obtained using the reported P value for change of baseline scores for control and
intervention groups respectively.
Notes Sponsorship source: None declared.
Country: Belgium.
Setting: Outpatient clinic.
Author name: Yvan Vandenplas.
Institution: Loeb Academic Children’s Hospital, Free University of Brussels
Email: Yvan.Vandenplas@uzbrussel.be
Address: Loeb Academic Children’s Hospital, Free University of Brussels, Laarbeeklaan
101, B-1090 Brussels, Belgium
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Infants were randomised to thickened or
unthickened formula in an alternate man-
ner based on order of presentation to the
clinic (information provided by author)
Allocation concealment (selection bias) High risk Infants were randomised to thickened or
unthickened formula in an alternate man-
ner based on order of presentation to the
clinic (information provided by author)
Blinding of participants and personnel
(performance bias)
Symptoms or signs of gastro-oesophageal
reflux and side effect
High risk Blinding was performed using anonymous
milk tins. Neither parents nor physicians
knew the content of the formula during
the study period. Parents were informed
that the study investigated a ’new’ formula
rather than a ’thickened’ formula (informa-
tion from author). However, parents could
have noticed the higher viscosity of the an-
tiregurgitation formula, which may have
affected parental report of signs or symp-
toms
Blinding of participants and personnel
(performance bias)
Oesophageal pH probe study parameter
Low risk Potential of hydrogen probe study param-
eter is an objective measure of reflux and is
unlikely to be affected by blinding bias
Blinding of outcome assessment (detection
bias)
Symptoms or signs of gastro-oesophageal
reflux and side effects
High risk Blinding was performed using anonymous
milk tins. Neither parents nor physicians
knew the content of the formula during
the study period. Parents were informed
that the study investigated a ’new’ formula
rather than a ’thickened’ formula (informa-
tion from author). However, parents could
have noticed the higher viscosity of the an-
tiregurgitation formula, which may have
affected parental report of signs or symp-
toms
Blinding of outcome assessment (detection
bias)
Oesophageal pH probe study parameter
Low risk Potential of hydrogen probe study param-
eter is an objective measure of reflux and is
unlikely to be affected by blinding bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcomedatawere reported
and no exclusions were mentioned
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Selective reporting (reporting bias) Unclear risk All outcome measures described in the
methods section were reported. However,
the study protocol or trial registrationnum-
ber, or both, were not available
Other bias Low risk There were no reported differences in par-
ticipant characteristics at baseline
Vanderhoof 2003
Methods Study design: Randomised controlled trial.
Study grouping: Parallel group.
Participants Baseline characteristics
Control/placebo
• Total number of infants randomised: 49.
• Age (mean ±1 standard deviation): 58 ± 4 days.
• Sex: 53% male.
• Number of episodes of regurgitation/vomiting per day (mean ±1 standard deviation):
11 ± 1.
• Volume of formula intake (mean ±1 standard deviation): 713 ± 26 mL/day.
Feed thickener
• Total number of infants randomised: 55.
• Age (mean ±1 standard deviation): 61 ± 4 days.
• Sex: 49% male.
• Number of episodes of regurgitation/vomiting per day (mean ±1 standard deviation):
13 ± 1.
• Volume of formula intake, mL/day (mean ±1 standard deviation): 747 ± 26 mL/day.
Inclusion criteria: Infants with more than 5 regurgitations per day for 2 baseline days,
age between 14 and 120 days, gestational age at birth > 37 weeks, birth weight > 2500
g, and maternal age > 18 years were included
Exclusion criteria: Disease or congenital anomalies interfering with normal feeding or
causing repeated regurgitation, fever or infectious illness at enrolment, clinical diagnosis
ofmilk or soy protein allergy, complicated gastro-oesophageal refluxdisease (oesophagitis,
haematemesis, recurrent respiratory symptoms, failure to thrive), previous treatment
with thickened formula, or treatment with prokinetic medication within 5 days before
the start of the study
Pretreatment: Baseline demographics and clinical parameters were similar between in-
fants in the intervention and control groups except for the total regurgitation volume
score, which was worse in the intervention group. The total regurgitation volume score
is a measure of the volume of the largest regurgitation after each bottle of the day
6 randomised infants were excluded as they did not receive the study formula
Study period: 18 months (December 1996 to July 1998).
Interventions Intervention characteristics
Control/placebo
• Type of control: Standard formula.
• Duration of intervention: 5 weeks.
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• Co-intervention: Not mentioned.
• Compliance: 13 infants discontinued the feed during the study, 10 for formula
reasons and 3 for non-formula reasons.
Feed thickener
• Type of feed thickener: Antiregurgitation formula (Enfamil AR) containing rice
cereal.
• Duration of intervention: 5 weeks.
• Co-intervention: Not mentioned.
• Compliance: 9 infants discontinued the feed during the study, 7 for formula
reasons and 2 for non-formula reasons.
Outcomes Outcomes were reported after 5 weeks of intervention.
Number of episodes of regurgitation, posseting, or vomiting per day
• Outcome type: Continuous outcome.
• Reporting: Partially reported.
• Data value: Change from baseline score was used.
• Notes: Reported standard errors were used to obtain the standard deviation.
Notes Sponsorship source: This study was supported by a grant from Mead Johnson & Co.
to each of the recruitment sites
Country: USA and Canada.
Setting: 6 North American paediatric centres.
Comments:
Author name: Jon A Vanderhoof.
Institution: University of Nebraska Medical Center and Creighton University
Email: Jon.Vanderhoof@childrens.harvard.edu
Address: Joint Section of Pediatric Gastroenterology and Nutrition, University of Ne-
braska Medical Center and Creighton University, Omaha, Nebraska
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computerised randomisation schedule
was prepared for each study site (informa-
tion obtained from author)
Allocation concealment (selection bias) Low risk Each site was supplied with sealed en-
velopes containing the product code of the
formula that the infant was to receive after
verifying inclusion/exclusion criteria (in-
formation obtained from author)
Blinding of participants and personnel
(performance bias)
Symptoms or signs of gastro-oesophageal
reflux and side effect
High risk This was a double-blind trial. The study
products were only identified by a ran-
domly generated code, where each study
formula group received 2 codes. The prod-
ucts were similar otherwise (information
above obtained from author). However,
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parents were likely to note the higher vis-
cosity of the thickened feed
Blinding of participants and personnel
(performance bias)
Oesophageal pH probe study parameter
Low risk Not applicable
Blinding of outcome assessment (detection
bias)
Symptoms or signs of gastro-oesophageal
reflux and side effects
High risk This was a double-blind trial. The study
products were only identified by a ran-
domly generated code, where each study
formula group received 2 codes. The prod-
ucts were similar otherwise (information
above obtained from author). However,
parents were likely to note the higher vis-
cosity of the thickened feed
Blinding of outcome assessment (detection
bias)
Oesophageal pH probe study parameter
Low risk Not applicable
Incomplete outcome data (attrition bias)
All outcomes
High risk 84% of infants in intervention group and
73% in the control group completed the 5-
week study. Outcome measures at the end
of the studywere reported in 91%and 98%
of infants in the intervention and control
groups, respectively. However, more than
10%of infants in the intervention and con-
trol groups did not complete the study. The
data entered in the final outcome measures
were based on the last data available prior
to discontinuation from the study
Selective reporting (reporting bias) Unclear risk All outcome measures described in the
methods section were reported. However,
study protocol or trial registration number,
or both, were not available
Other bias High risk This study was supported by a grant from
Mead Johnson&Co. to each of the recruit-
ment sites
Infants in the intervention group had a
worse average total regurgitation volume
score that those in the control group
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Methods Study design: Randomised controlled trial.
Study grouping: Parallel group.
Participants Baseline characteristics
Control/placebo
• Total number of infants randomised: 45.
• Age (mean ± 1 standard deviation): 94 ± 32 days.
• Number of episodes of regurgitation/vomiting per day (mean ±1 standard deviation):
4.77 ± 2.35.
• Volume of formula intake, mL/kg/day (mean ±1 standard deviation): 130 to 160
mL/kg/day.
Feed thickener
• Total number of infants randomised: 51.
• Age, days (mean ±1 standard deviation): 92 ± 35 days.
• Number of episodes of regurgitation/vomiting per day (mean ±1 standard deviation):
5.60 ± 4.15.
• Volume of formula intake, mL/kg/day (mean ±1 standard deviation): 130 to 160
mL/kg/day.
Inclusion criteria: All infants were term, exclusively formula-fed, and ‘healthy’, except
for excessive regurgitation and/or vomiting and abnormal pH probe study parameters
of reflux index > 5%
Exclusion criteria: Infants who were very irritable or had haematemesis, passed black
stools, had chronic cough, had episodes of cyanosis, or had any other medical problems
were excluded. Infants on a dietetic formula (such as hydrolysed or soy-based formula)
were excluded, as the specialised formula is considered as a therapeutic intervention
Pretreatment: At baseline, infants in the feed thickener group had a higher number of
episodes of vomiting per day than the control group (4.34 ± 2.42 vs 3.09 ± 1.24), but
no difference in number of episodes of regurgitation per day
Study period: Not reported.
Interventions Intervention characteristics
Control/placebo
• Type of control: Standard formula.
• Duration of intervention: 3.7 ± 0.7 weeks.
• Co-intervention: Not mentioned.
• Others: Casein:whey ratio 50:50 and 18.6% medium-chain triglyceride.
Feed thickener
• Type of feed thickener: Formula thickened with specially treated re-gelatinised
cornstarch.
• Duration of intervention: 3.7 ± 0.7 weeks.
• Co-intervention: Not mentioned.
• Others: Casein:whey ratio 80:20 and 19.4% medium-chain triglyceride.
Outcomes Outcomes were reported after 4 weeks of intervention.
Number of episodes of regurgitation, posseting, or vomiting per day
• Outcome type: Continuous outcome.
• Reporting: Partially reported.
• Data value: Change from baseline score was used.
• Notes: Study reported both frequency of regurgitation and vomiting. Number of
episodes of regurgitation per day was used rather than vomiting. Standard deviations
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for change of baseline scores were not reported. They were obtained using the reported
P value for change of baseline scores for control and intervention groups respectively.
Reflux index
• Outcome type: Continuous outcome.
• Reporting: Partially reported.
• Unit of measure: Percentage change.
• Data value: Change from baseline score was used.
• Notes: Standard deviations for change of baseline scores were not reported. They
were obtained using the reported P value for change of baseline scores for control and
intervention groups respectively.
Number of reflux episodes per hour
• Outcome type: Continuous outcome.
• Reporting: Partially reported.
• Data value: Change from baseline score was used.
• Notes: Standard deviations for change of baseline scores were not reported. They
were obtained using the reported P value for change of baseline scores for control and
intervention groups respectively.
Number of reflux episodes lasting > 5 minutes
• Outcome type: Continuous outcome.
• Reporting: Partially reported.
• Data value: Change from baseline score was used.
• Notes: Standard deviations for change of baseline scores were not reported. They
were obtained using the reported P value for change of baseline scores for control and
intervention groups respectively.
Duration of longest episode
• Outcome type: Continuous outcome.
• Reporting: Partially reported.
• Unit of measure: Minutes.
• Data value: Change from baseline score was used.
• Notes: Standard deviations for change of baseline scores were not reported. They
were obtained using the reported P value for change of baseline scores for control and
intervention groups respectively.
Side effect
• Outcome type: Dichotomous outcome.
• Reporting: Partially reported.
• Notes: No side effects due to the intervention were recorded.
Notes Sponsorship source:United Pharmaceuticals provided funding of formula Novalac AR
for the participating infants up to a maximal period of 3 months
Country:Multinational (Greece, Morocco, France, and Belgium).
Setting: Outpatients.
Comments:
Author name: Yvan Vandenplas.
Institution: Paediatric Gastroenterology, Academisch Ziekenhuis Vrije Universiteit
Brussel
Email: yvan.vandenplas@az.vub.ac.be
Address: Paediatric Gastroenterology, Academisch Ziekenhuis Vrije Universiteit Brussel,
Laarbeeklaan 101, 1090 Brussels, Belgium
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation was not men-
tioned.
Allocation concealment (selection bias) Low risk Allocation was concealed using sealed en-
velopes.
Blinding of participants and personnel
(performance bias)
Symptoms or signs of gastro-oesophageal
reflux and side effect
High risk Parentswere blinded to the formulae.How-
ever, they were able to observe that the
thickened formula had a higher viscosity,
which may have affected parent-reported
symptoms or signs of gastro-oesophageal
reflux
Blinding of participants and personnel
(performance bias)
Oesophageal pH probe study parameter
Low risk Although parents were blinded to the for-
mulae, they were able to observe that the
thickened formula had a higher viscosity.
However, this should not affect objective
pH probe study parameters
Blinding of outcome assessment (detection
bias)
Symptoms or signs of gastro-oesophageal
reflux and side effects
High risk Parentswere blinded to the formulae.How-
ever, they were able to observe that the
thickened formula had a higher viscosity,
which may have affected parent-reported
symptoms or signs of gastro-oesophageal
reflux
Blinding of outcome assessment (detection
bias)
Oesophageal pH probe study parameter
Low risk Although parents were blinded to the for-
mulae, they were able to observe that the
thickened formula had a higher viscosity.
However, this should not affect objective
pH probe study parameters
Incomplete outcome data (attrition bias)
All outcomes
Low risk None of the infants dropped out.
Selective reporting (reporting bias) Unclear risk All outcome measures described in the
methods section were reported. However,
study protocol or trial registration number,
or both, were not available
Other bias High risk United Pharmaceuticals provided funding
of formulaNovalacAR for the participating
infants up to amaximal period of 3months.
At baseline, infants in the feed thickener
group had a higher number episodes of
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vomiting per day than the control group
(4.34 ± 2.42 vs 3.09 ± 1.24), but there was
no difference in number of episodes of re-
gurgitation per day. Regurgitation was de-
fined as the effortless passage of refluxed
gastric contents into the oral pharynx and
the mouth with effortless drooling out of
the mouth, whereas vomiting was defined
as forceful expulsion of the refluxed gastric
contents from the mouth
GOR: gastro-oesophageal reflux
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Atasay 2010 This was a before-after study design and not a randomised controlled trial. All preterm infants received sodium
alginate with potassium bicarbonate
Bailey 1987 Participant ages ranged from 4 days to 14 months. This was a cross-over study in which each participant received
both thickened and unthickened feeds
Borrelli 1997 Participant ages ranged from 5 to 11 months. All infants received either a traditional formula thickened with rice
flour at a concentration of 5% or antiregurgitation formula Nutrilon AR, which contained locus bean gum as
thickener. There was no control group
Chao 2007a This was a randomised clinical trial comparing cereal-thickened formula versus postural therapy. There was no
placebo or control group
Chevallier 1998 This was a cohort study where all infants received formula thickened with cornstarch. Participant ages ranged
from 2 weeks to 11 months
Chevallier 2009 This was a open, uncontrolled, multicentre cohort study. All infants received formula thickened with starch
Corvaglia 2006 This was a cross-over study. All 5 preterm infants in the study received fortified humanmilk thickened with starch
(70% from maize and 30% from potato)
Corvaglia 2011 This was a cross-over study. All 28 preterm infants in the study received Gaviscon, which contains both sodium
alginate and sodium bicarbonate
Corvaglia 2011a This was a cross-over study. All 32 preterm infants in the study received Gaviscon, which contains both sodium
alginate and sodium bicarbonate
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Corvaglia 2012 This was a cross-over study. All 28 preterm infants in the study received preterm formula thickened with amy-
lopectin
Craig 2002 This is not a study, but rather an expert opinion piece on the topic
Dupont 2016 This was a before-after study design and not a randomised controlled trial. All 100 recruited infants received
antiregurgitation formula with baseline and postintervention outcomes measured
EBP 2004 This is not a study, but rather an expert opinion piece on the topic
Fabiani 2000 This was a cross-over study investigating the impact of formula thickened with carob seed galactomannans on
ultrasonographic evaluation of gastric emptying time. Participant ages ranged from 1 to 12 months
Georgieva 2016 There was no control group in this randomised clinical trial. Infants in all 3 arms of the trial received formula
thickened with carob bean gum galactomannans in varying doses or temperatures
Gouyon 1988 This was a cross-over study. All 20 preterm infants in the study received smectite and postural therapy
Khoshoo 2000 This was a cohort study. All 6 infants received a smaller volume of formula thickened with dry rice cereal and
postural therapy. Participant ages ranged from 4 to 10 months
Lasekan 2014 This was a multicentre randomised controlled trial that recruited healthy term infants without regard to signs or
symptoms of gastro-oesophageal reflux. The intervention was a formula thickened with rice starch that was also
lactose free. The control was an unthickened formula with lactose
Miyazawa 2006 This was not a randomised controlled trial. The first part of the study investigated the impact of formula thickened
with carob flour on ultrasonographic evaluation of gastric emptying time. The second part of the study was a
cross-over trial where all 27 infants received formula thickened with carob flour
Miyazawa 2007 This was a cross-over study where each infant received both thickened and unthickened feeds
Moukarzel 2007 This was a cross-over study where each infant received both thickened and unthickened feeds
Orenstein 1992 This was a cross-over study where each infant received both dry rice cereal-thickened and unthickened feeds
Ostrom 2006 The intervention in this randomised controlled trial was a soy protein-based formula thickened with soy fibre,
whereas the control was an unthickened whey protein-based formula. Hence, there was co-intervention of both
thickening and substituting soy protein-based formula
Penna 2003 This was not a randomised controlled trial but rather a prospective case control investigating the effect of formula
thickened with home-prepared cornstarch versus antiregurgitation formula. Hence, there was no suitable control.
Participant ages ranged from 0 to 12 months
Savino 2008 This is not a study, but rather an expert opinion piece on the topic
Tolia 1999 The trial included infants up to 1 year old.
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Toporovski 2013 The trial did not report outcome measure specified in the review
Ummarino 2013 The trial included infants up to 1 year old with a mean age of 5.56 ± 2.34 months
Wenzl 2003 This was a cross-over study where each infant received both carob bean gum-thickened and unthickened feeds
Xinias 2003 This study is not a randomised controlled trial, but rather a non-randomised open-label study
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D A T A A N D A N A L Y S E S
Comparison 1. Regurgitation, posseting, or vomiting
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of episodes per day 6 442 Mean Difference (IV, Fixed, 95% CI) -1.97 [-2.32, -1.61]
1.1 Rice cereal 2 127 Mean Difference (IV, Fixed, 95% CI) -1.43 [-3.36, 0.49]
1.2 Carob bean gum 2 39 Mean Difference (IV, Fixed, 95% CI) -1.47 [-3.13, 0.19]
1.3 Cornstarch 3 188 Mean Difference (IV, Fixed, 95% CI) -1.98 [-2.35, -1.61]
1.4 Alginate 1 88 Mean Difference (IV, Fixed, 95% CI) -3.5 [-6.07, -0.93]
2 Proportion of asymptomatic
infants
2 186 Risk Ratio (M-H, Fixed, 95% CI) 2.50 [1.38, 4.51]
2.1 Carob bean gum 2 186 Risk Ratio (M-H, Fixed, 95% CI) 2.50 [1.38, 4.51]
Comparison 2. Oesophageal pH probe study parameters
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reflux Index (percentage of time
pH < 4)
2 116 Mean Difference (IV, Fixed, 95% CI) -5.08 [-8.89, -1.28]
1.1 Carob bean gum 1 20 Mean Difference (IV, Fixed, 95% CI) -3.90 [-9.36, 1.56]
1.2 Cornstarch 1 96 Mean Difference (IV, Fixed, 95% CI) -6.20 [-11.50, -0.90]
2 Number of reflux episodes
lasting > 5 minutes
2 116 Mean Difference (IV, Fixed, 95% CI) -3.40 [-5.44, -1.36]
2.1 Carob bean gum 1 20 Mean Difference (IV, Fixed, 95% CI) -3.4 [-7.06, 0.26]
2.2 Cornstarch 1 96 Mean Difference (IV, Fixed, 95% CI) -3.40 [-5.85, -0.95]
3 Duration of longest reflux
episode (minutes)
2 116 Mean Difference (IV, Fixed, 95% CI) -12.41 [-23.25, -1.
58]
3.1 Carob bean gum 1 20 Mean Difference (IV, Fixed, 95% CI) -1.80 [-24.63, 21.
03]
3.2 Cornstarch 1 96 Mean Difference (IV, Fixed, 95% CI) -15.5 [-27.81, -3.19]
Comparison 3. Sensitivity analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Endpoint value - number of
episodes of regurgitation,
posseting, or vomiting per day
5 345 Mean Difference (IV, Fixed, 95% CI) -1.91 [-2.24, -1.58]
1.1 Rice cereal 1 30 Mean Difference (IV, Fixed, 95% CI) -1.20 [-2.90, 0.50]
1.2 Carob bean gum 2 39 Mean Difference (IV, Fixed, 95% CI) -1.90 [-3.25, -0.56]
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1.3 Cornstarch 3 188 Mean Difference (IV, Fixed, 95% CI) -1.94 [-2.29, -1.59]
1.4 Alginate 1 88 Mean Difference (IV, Fixed, 95% CI) -2.0 [-5.15, 1.15]
2 Endpoint value - reflux index
(percentage of time pH < 4)
2 116 Mean Difference (IV, Fixed, 95% CI) -4.01 [-6.33, -1.68]
2.1 Carob bean gum 1 20 Mean Difference (IV, Fixed, 95% CI) -2.10 [-6.87, 2.67]
2.2 Cornstarch 1 96 Mean Difference (IV, Fixed, 95% CI) -4.60 [-7.26, -1.94]
3 Endpoint value - number of
reflux episodes lasting > 5
minutes
2 116 Mean Difference (IV, Fixed, 95% CI) -2.24 [-3.62, -0.85]
3.1 Carob bean gum 1 20 Mean Difference (IV, Fixed, 95% CI) -1.10 [-4.30, 2.10]
3.2 Cornstarch 1 96 Mean Difference (IV, Fixed, 95% CI) -2.50 [-4.04, -0.96]
4 Endpoint value - duration of
longest reflux episode (minutes)
2 116 Mean Difference (IV, Fixed, 95% CI) -8.09 [-11.93, -4.25]
4.1 Carob bean gum 1 20 Mean Difference (IV, Fixed, 95% CI) 1.20 [-17.44, 19.84]
4.2 Cornstarch 1 96 Mean Difference (IV, Fixed, 95% CI) -8.5 [-12.42, -4.58]
Analysis 1.1. Comparison 1 Regurgitation, posseting, or vomiting, Outcome 1 Number of episodes per day.
Review: Feed thickener for infants up to six months of age with gastro-oesophageal reflux
Comparison: 1 Regurgitation, posseting, or vomiting
Outcome: 1 Number of episodes per day
Study or subgroup Feed thickener Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Rice cereal
Hegar 2008 20 -3.6 (5.0728) 10 -2.7 (2.4) 1.7 % -0.90 [ -3.57, 1.77 ]
Vanderhoof 2003 50 -7 (7.0711) 47 -5 (6.8557) 1.6 % -2.00 [ -4.77, 0.77 ]
Subtotal (95% CI) 70 57 3.4 % -1.43 [ -3.36, 0.49 ]
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.15)
2 Carob bean gum
Hegar 2008 20 -4.2 (2.1) 10 -2.7 (2.4) 4.1 % -1.50 [ -3.25, 0.25 ]
Moya 1999 6 -7.3 (3.7461) 3 -6.1 (3.7057) 0.5 % -1.20 [ -6.35, 3.95 ]
Subtotal (95% CI) 26 13 4.5 % -1.47 [ -3.13, 0.19 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.082)
3 Cornstarch
Chao 2007 41 0.93 (0.42) 40 2.89 (1.16) 85.4 % -1.96 [ -2.34, -1.58 ]
Moya 1999 8 -6.7 (3.5042) 3 -6.1 (3.7057) 0.5 % -0.60 [ -5.45, 4.25 ]
-4 -2 0 2 4
Favours Feed Thickener Favours Control
(Continued . . . )
58Feed thickener for infants up to six months of age with gastro-oesophageal reflux (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Feed thickener Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Xinias 2005 51 -3.03 (5.1175) 45 -0.46 (3.3359) 4.3 % -2.57 [ -4.28, -0.86 ]
Subtotal (95% CI) 100 88 90.2 % -1.98 [ -2.35, -1.61 ]
Heterogeneity: Chi2 = 0.78, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 10.45 (P < 0.00001)
4 Alginate
Miller 1999 42 -5.5 (6.1358) 46 -2 (6.1358) 1.9 % -3.50 [ -6.07, -0.93 ]
Subtotal (95% CI) 42 46 1.9 % -3.50 [ -6.07, -0.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.67 (P = 0.0075)
Total (95% CI) 238 204 100.0 % -1.97 [ -2.32, -1.61 ]
Heterogeneity: Chi2 = 3.13, df = 7 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 10.93 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.02, df = 3 (P = 0.57), I2 =0.0%
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Analysis 1.2. Comparison 1 Regurgitation, posseting, or vomiting, Outcome 2 Proportion of asymptomatic
infants.
Review: Feed thickener for infants up to six months of age with gastro-oesophageal reflux
Comparison: 1 Regurgitation, posseting, or vomiting
Outcome: 2 Proportion of asymptomatic infants
Study or subgroup Feed Thickener Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Carob bean gum
Iacono 2002 28/82 12/84 96.0 % 2.39 [ 1.31, 4.37 ]
Vandenplas 1994 2/10 0/10 4.0 % 5.00 [ 0.27, 92.62 ]
Total (95% CI) 92 94 100.0 % 2.50 [ 1.38, 4.51 ]
Total events: 30 (Feed Thickener), 12 (Control)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0024)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Oesophageal pH probe study parameters, Outcome 1 Reflux Index (percentage
of time pH < 4).
Review: Feed thickener for infants up to six months of age with gastro-oesophageal reflux
Comparison: 2 Oesophageal pH probe study parameters
Outcome: 1 Reflux Index (percentage of time pH < 4)
Study or subgroup Feed Thickener Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Carob bean gum
Vandenplas 1994 10 -8.1 (5.3576) 10 -4.2 (6.9932) 48.5 % -3.90 [ -9.36, 1.56 ]
Subtotal (95% CI) 10 10 48.5 % -3.90 [ -9.36, 1.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
2 Cornstarch
Xinias 2005 51 -8.1 (16.5462) 45 -1.9 (9.3551) 51.5 % -6.20 [ -11.50, -0.90 ]
Subtotal (95% CI) 51 45 51.5 % -6.20 [ -11.50, -0.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
Total (95% CI) 61 55 100.0 % -5.08 [ -8.89, -1.28 ]
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.62 (P = 0.0088)
Test for subgroup differences: Chi2 = 0.35, df = 1 (P = 0.55), I2 =0.0%
-10 -5 0 5 10
Favours Feed Thickener Favours Control
61Feed thickener for infants up to six months of age with gastro-oesophageal reflux (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Oesophageal pH probe study parameters, Outcome 2 Number of reflux
episodes lasting > 5 minutes.
Review: Feed thickener for infants up to six months of age with gastro-oesophageal reflux
Comparison: 2 Oesophageal pH probe study parameters
Outcome: 2 Number of reflux episodes lasting > 5 minutes
Study or subgroup Feed Thickener Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Carob bean gum
Vandenplas 1994 10 -2.8 (5.3137) 10 0.6 (2.5751) 31.0 % -3.40 [ -7.06, 0.26 ]
Subtotal (95% CI) 10 10 31.0 % -3.40 [ -7.06, 0.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
2 Cornstarch
Xinias 2005 51 -4.1 (6.9247) 45 -0.7 (5.2951) 69.0 % -3.40 [ -5.85, -0.95 ]
Subtotal (95% CI) 51 45 69.0 % -3.40 [ -5.85, -0.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.72 (P = 0.0065)
Total (95% CI) 61 55 100.0 % -3.40 [ -5.44, -1.36 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 3.27 (P = 0.0011)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 2.3. Comparison 2 Oesophageal pH probe study parameters, Outcome 3 Duration of longest
reflux episode (minutes).
Review: Feed thickener for infants up to six months of age with gastro-oesophageal reflux
Comparison: 2 Oesophageal pH probe study parameters
Outcome: 3 Duration of longest reflux episode (minutes)
Study or subgroup Feed Thickener Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Carob bean gum
Vandenplas 1994 10 -12.2 (26.5395) 10 -10.4 (25.5414) 22.5 % -1.80 [ -24.63, 21.03 ]
Subtotal (95% CI) 10 10 22.5 % -1.80 [ -24.63, 21.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
2 Cornstarch
Xinias 2005 51 -20 (40.8547) 45 -4.5 (17.4133) 77.5 % -15.50 [ -27.81, -3.19 ]
Subtotal (95% CI) 51 45 77.5 % -15.50 [ -27.81, -3.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.47 (P = 0.014)
Total (95% CI) 61 55 100.0 % -12.41 [ -23.25, -1.58 ]
Heterogeneity: Chi2 = 1.07, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Chi2 = 1.07, df = 1 (P = 0.30), I2 =7%
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Analysis 3.1. Comparison 3 Sensitivity analysis, Outcome 1 Endpoint value - number of episodes of
regurgitation, posseting, or vomiting per day.
Review: Feed thickener for infants up to six months of age with gastro-oesophageal reflux
Comparison: 3 Sensitivity analysis
Outcome: 1 Endpoint value - number of episodes of regurgitation, posseting, or vomiting per day
Study or subgroup Feed Thickener Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Rice cereal
Hegar 2008 20 2.1 (2.1) 10 3.3 (2.3) 3.8 % -1.20 [ -2.90, 0.50 ]
Subtotal (95% CI) 20 10 3.8 % -1.20 [ -2.90, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
2 Carob bean gum
Hegar 2008 20 1.3 (1.4) 10 3.3 (2.3) 4.5 % -2.00 [ -3.55, -0.45 ]
Moya 1999 6 2.9 (1.6) 3 4.5 (2.1) 1.5 % -1.60 [ -4.30, 1.10 ]
Subtotal (95% CI) 26 13 6.0 % -1.90 [ -3.25, -0.56 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.77 (P = 0.0056)
3 Cornstarch
Chao 2007 41 0.93 (0.42) 40 2.89 (1.16) 75.1 % -1.96 [ -2.34, -1.58 ]
Moya 1999 8 2.2 (1) 3 4.5 (2.1) 1.8 % -2.30 [ -4.78, 0.18 ]
Xinias 2005 51 2.57 (2.71) 45 4.31 (2.01) 12.2 % -1.74 [ -2.69, -0.79 ]
Subtotal (95% CI) 100 88 89.0 % -1.94 [ -2.29, -1.59 ]
Heterogeneity: Chi2 = 0.26, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 10.83 (P < 0.00001)
4 Alginate
Miller 1999 42 3 (5.5) 46 5 (9.25) 1.1 % -2.00 [ -5.15, 1.15 ]
Subtotal (95% CI) 42 46 1.1 % -2.00 [ -5.15, 1.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Total (95% CI) 188 157 100.0 % -1.91 [ -2.24, -1.58 ]
Heterogeneity: Chi2 = 1.02, df = 6 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 11.30 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.70, df = 3 (P = 0.87), I2 =0.0%
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Analysis 3.2. Comparison 3 Sensitivity analysis, Outcome 2 Endpoint value - reflux index (percentage of
time pH < 4).
Review: Feed thickener for infants up to six months of age with gastro-oesophageal reflux
Comparison: 3 Sensitivity analysis
Outcome: 2 Endpoint value - reflux index (percentage of time pH < 4)
Study or subgroup Feed Thickener Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Carob bean gum
Vandenplas 1994 10 11.1 (6.1) 10 13.2 (4.7) 23.7 % -2.10 [ -6.87, 2.67 ]
Subtotal (95% CI) 10 10 23.7 % -2.10 [ -6.87, 2.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
2 Cornstarch
Xinias 2005 51 6.8 (6.2) 45 11.4 (7) 76.3 % -4.60 [ -7.26, -1.94 ]
Subtotal (95% CI) 51 45 76.3 % -4.60 [ -7.26, -1.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.39 (P = 0.00070)
Total (95% CI) 61 55 100.0 % -4.01 [ -6.33, -1.68 ]
Heterogeneity: Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 3.38 (P = 0.00073)
Test for subgroup differences: Chi2 = 0.80, df = 1 (P = 0.37), I2 =0.0%
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Analysis 3.3. Comparison 3 Sensitivity analysis, Outcome 3 Endpoint value - number of reflux episodes
lasting > 5 minutes.
Review: Feed thickener for infants up to six months of age with gastro-oesophageal reflux
Comparison: 3 Sensitivity analysis
Outcome: 3 Endpoint value - number of reflux episodes lasting > 5 minutes
Study or subgroup Feed Thickener Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Carob bean gum
Vandenplas 1994 10 7.7 (4.27) 10 8.8 (2.9) 18.8 % -1.10 [ -4.30, 2.10 ]
Subtotal (95% CI) 10 10 18.8 % -1.10 [ -4.30, 2.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 Cornstarch
Xinias 2005 51 2.9 (3.4) 45 5.4 (4.2) 81.2 % -2.50 [ -4.04, -0.96 ]
Subtotal (95% CI) 51 45 81.2 % -2.50 [ -4.04, -0.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.18 (P = 0.0015)
Total (95% CI) 61 55 100.0 % -2.24 [ -3.62, -0.85 ]
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.16 (P = 0.0016)
Test for subgroup differences: Chi2 = 0.60, df = 1 (P = 0.44), I2 =0.0%
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Analysis 3.4. Comparison 3 Sensitivity analysis, Outcome 4 Endpoint value - duration of longest reflux
episode (minutes).
Review: Feed thickener for infants up to six months of age with gastro-oesophageal reflux
Comparison: 3 Sensitivity analysis
Outcome: 4 Endpoint value - duration of longest reflux episode (minutes)
Study or subgroup Feed Thickener Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Carob bean gum
Vandenplas 1994 10 31.1 (23.4) 10 29.9 (18.9) 4.2 % 1.20 [ -17.44, 19.84 ]
Subtotal (95% CI) 10 10 4.2 % 1.20 [ -17.44, 19.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
2 Cornstarch
Xinias 2005 51 10.8 (8.9) 45 19.3 (10.5) 95.8 % -8.50 [ -12.42, -4.58 ]
Subtotal (95% CI) 51 45 95.8 % -8.50 [ -12.42, -4.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.25 (P = 0.000022)
Total (95% CI) 61 55 100.0 % -8.09 [ -11.93, -4.25 ]
Heterogeneity: Chi2 = 1.00, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 4.13 (P = 0.000036)
Test for subgroup differences: Chi2 = 1.00, df = 1 (P = 0.32), I2 =0.0%
-10 -5 0 5 10
Favours Feed Thickener Favours Control
A P P E N D I C E S
Appendix 1. Standard search methodology
Review specific terms: (“Gastroesophageal Reflux”[Mesh] OR Gastroesophageal Reflux OR gastro-oesophageal reflux) AND (thick*
OR diet OR antiregurg* OR conserv* OR non-pharmaco* OR nonpharmaco*)
AND
Database specific terms:
PubMed: ((infant, newborn[MeSH] OR newborn OR neonate OR neonatal OR premature OR low birth weight ORVLBWOR LBW
or infan* or neonat*) AND (randomized controlled trial [pt] OR controlled clinical trial [pt] OR Clinical Trial[ptyp] OR randomized
[tiab] OR placebo [tiab] OR clinical trials as topic [mesh: noexp] OR randomly [tiab] OR trial [ti]) NOT (animals [mh] NOT humans
[mh]))
Embase: (infant, newborn or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or
LBW or Newborn or infan* or neonat*) AND (human not animal) AND (randomized controlled trial or controlled clinical trial or
randomized or placebo or clinical trials as topic or randomly or trial or clinical trial)
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CINAHL: (infant, newborn OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or
Newborn or infan* or neonat*) AND (randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR clinical
trials as topic OR randomly OR trial OR PT clinical trial)
Cochrane Library: (infant or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or
LBW)
Appendix 2. ’Risk of bias’ tool
We used the standard methods of Cochrane and Cochrane Neonatal to assess themethodological quality (to meet the validity criteria) of
the trials. For each trial, we sought information regarding the method of randomisation and the blinding and reporting of all outcomes
of all infants enrolled in the trial. We assessed each criterion as low, high, or unclear risk. Two review authors independently assessed
each study. Any disagreements were resolved by discussion. We added this information to the Characteristics of included studies table.
We evaluated the following issues and entered the findings into the ’Risk of bias’ table.
1. Sequence generation (checking for possible selection bias). Was the allocation sequence adequately generated?
For each included study, we categorised the method used to generate the allocation sequence as:
a. low risk (any truly random process, e.g. random number table, computer random number generator);
b. high risk (any non-random process, e.g. odd or even date of birth, hospital or clinic record number);
c. unclear risk.
2. Allocation concealment (checking for possible selection bias). Was allocation adequately concealed?
For each included study, we categorised the method used to conceal the allocation sequence as:
a. low risk (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes);
b. high risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);
c. unclear risk.
3. Blinding of participants and personnel (checking for possible performance bias). Was knowledge of the allocated intervention
adequately prevented during the study?
For each included study, we categorised the methods used to blind study participants and personnel from knowledge of which
intervention a participant received. Blinding was assessed separately for different outcomes or class of outcomes. We categorised the
methods as:
a. low risk, high risk, or unclear risk for participants;
b. low risk, high risk, or unclear risk for personnel.
4. Blinding of outcome assessment (checking for possible detection bias). Was knowledge of the allocated intervention adequately
prevented at the time of outcome assessment?
For each included study, we categorised the methods used to blind outcome assessment. Blinding was assessed separately for different
outcomes or class of outcomes. We categorised the methods as:
a. low risk for outcome assessors;
b. high risk for outcome assessors;
c. unclear risk for outcome assessors.
5. Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations). Were incomplete
outcome data adequately addressed?
For each included study and for each outcome, we described the completeness of the data, including attrition and exclusions from the
analysis. We noted whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with
the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across
groups or were related to outcomes. Where sufficient information was reported or supplied by the trial authors, we re-included missing
data in the analyses. We categorised the methods as:
a. low risk (< 20% missing data);
b. high risk (≥ 20% missing data);
c. unclear risk.
6. Selective reporting bias. Are reports of the study free of the suggestion of selective outcome reporting?
For each included study, we described how we investigated the possibility of selective outcome reporting bias and what we found. We
assessed the methods as:
a. low risk (where it is clear that all of the study’s prespecified outcomes and all expected outcomes of interest to the review have been
reported);
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b. high risk (where not all of the study’s prespecified outcomes have been reported; one or more reported primary outcomes were not
prespecified outcomes of interest and are reported incompletely and so cannot be used; study fails to include results of a key outcome
that would have been expected to have been reported);
c. unclear risk.
7. Other sources of bias. Did the study appear to be free of other problems that could put it at high risk of bias?
For each included study, we described any important concerns we had about other possible sources of bias (e.g. whether there was a
potential source of bias related to the specific study design or whether the trial was stopped early due to some data-dependent process).
We assessed whether each study was free of other problems that could put it at risk of bias as:
a. low risk;
b. high risk;
c. unclear risk.
If needed, we explored the impact of the level of bias by undertaking sensitivity analyses.
WH A T ’ S N E W
Last assessed as up-to-date: 22 November 2016.
Date Event Description
28 June 2017 New citation required and conclusions have changed Studies are now eligible for inclusion and to inform
conclusions
22 November 2016 New search has been performed We expanded the age criterion to full-term infants up
to six months old and preterm infants up to sixmonths
corrected age
H I S T O R Y
Protocol first published: Issue 3, 2001
Review first published: Issue 3, 2002
Date Event Description
21 October 2008 Amended Converted to new review format.
17 April 2004 New search has been performed This is an update of the review ’Feed thickener for new-
born infants with gastro-oesophageal reflux’ published
in the Cochrane Library, Issue 3, 2002 (Huang 2002).
We searched for additional studies using the same criteria
and identified four additional studies, whichwe excluded
from the review. We identified no new trials fulfilling
our inclusion criteria. There are therefore no substantive
changes in the review update
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(Continued)
11 March 2002 New citation required and conclusions have changed Substantive amendment
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have made the following changes since the last update of the review in 2002.
• We expanded the age criteria for the participants from ’full-term infants less than 28 days and preterm infants up to 44 weeks
corrected age’ to ‘full-term infants less than six months and preterm infants up to six months corrected age’, because the majority of
infants present with uncomplicated reflux only after the first two to three weeks of life (Meunier 2014; Vandenplas 2009; Vandenplas
2015). Reassurance and parental education is the usual first-line management for uncomplicated reflux (Vandenplas 2015), and feed
thickeners are rarely started in the first 28 days of life. We used the six-month cut-off due to the natural progression of GOR, which is
believed to start improving by six months of age, when the infant starts on a more solid diet and achieves neurodevelopmental
maturation to maintain a more upright posture (Nelson 1997).
• We included Gaviscon Infant (alginate preparation without antacid) as an eligible intervention for inclusion in the review. We
excluded other preparations of Gaviscon or alginate with antacid components. Gaviscon Infant works primarily by thickening the
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feed and does not have antacid properties, unlike other preparations of Gaviscon. We performed a subgroup analysis to determine if
the results differed when trials investigating Gaviscon Infant as feed thickener were excluded.
• We streamlined the primary outcomes to three outcome measures that we felt to be important to parents, caregivers, and
clinicians. They were: i) regurgitation, posseting, or vomiting; ii) failure to thrive; and iii) reflux index. We analysed the remaining
outcome measures as secondary outcome measures.
• We also noted number of episodes per day of: i) regurgitation, posseting, vomiting, or haematemesis; ii) respiratory symptoms
(cough, apnoeas, and recurrent oxygen desaturation); and iii) bradycardias as continuous and separate outcomes. We used change
from baseline measurements in preference to final measurements.
• We did not assess cough as a side effect of feed thickener, as it was already considered to be a symptom of GOR.
• We carried out sensitivity analyses to explore the effect of change from baseline versus endpoint values on the analysis.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Food Additives [∗therapeutic use]; Gastroesophageal Reflux [∗therapy]
MeSH check words
Humans; Infant, Newborn
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